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NUAK2 amplification coupled with PTEN deficiency promote melanoma development via 
CDK activation
T Namiki,1 T Yaguchi,2 K Nakamura,2 M Kawaguchi,3 A Tanemura,4 I Katayama,4 
H Yokozeki,1 Y Kawakami2 and V Hearing3 1 Dermatology, Tokyo Medical and Dental 
University, Tokyo, Japan, 2 Division of Cellular Signaling, Keio University School of Medicine, 
Institute for Advanced Medical Research, Tokyo, Japan, 3 Laboratory of Cell Biology, National 
Cancer Institute, Bethesda, MD and 4 Dermatology, Osaka University Graduate School of 
Medicine, Osaka, Japan
We previously reported that amplification of the AMPK-related kinase NUAK2 is involved in the 
proliferation and migration of human melanoma cells. In this study, we have investigated that its 
genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors 
as a possible therapeutic strategy. We used a public array comparative genomic hybridization 
(CGH) database and immunohistochemistry for the analyses of clinical samples. We analyzed 
its functions using Lentiviral vectors carrying shRNA targeting NUAK2 in NUAK2-amplified and 
PTEN-deficient acral melanoma cells and effects of CDK2 inhibitors in vitro and in vivo. Array-CGH 
analysis revealed that PTEN deficiency was associated with genomic amplification encompassing 
the NUAK2 locus, and increase of phospho-Akt was correlated with NUAK2 expression when 
immunohistochemically evaluated in acral melanoma samples. Combination of NUAK2 silencing 
and pharmacological PI3K inactivation was found to significantly decrease CDK2 expression, and 
CDK2 inhibitor alone was sufficient to decrease the growth of NUAK2-amplified and PTEN-defi-
cient human melanoma cells. Immunohistochemical analyses confirmed the association of CDK2 
expression with NUAK2 amplification and p-Akt expression in melanoma samples. These results 
indicate that CDK2 inhibition is an attractive strategy for treatment of patients with melanoma 
harboring both amplified NUAK2 and PTEN deletion.    
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Interfering with stem cell-specific gatekeeper mechanisms and p53 activity results in mutant 
Lef1-driven skin tumour formation
K Reuter and C Niemann Center for Biochemistry II and Center for Molecular Medicine 
Cologne, University of Cologne, Cologne, Germany
Recent studies indicated that epidermal stem cells (SCs), which are crucial for maintaining skin 
homeostasis, respond differently to stress and DNA damage compared to their rapidly cycling 
progeny. Hair follicle (HF) bulge SCs possess SC-specific surveillance mechanisms. In particular, 
multipotent HF SCs are more resistant to DNA-damage-induced cell death, which has been linked 
to a higher expression of the pro-survival factor Bcl2 and attenuated p53 activation. Here, the 
relevance of these SC-specific gatekeeper functions for the process of skin tumour initiation has 
been investigated in vivo. To this end a mutant form of the transcription factor Lef1, mimicking 
mutations found in human epidermal tumours, was expressed specifically within the HF bulge 
SC compartment. Interestingly, targeted expression of mutant Lef1 results in SC-driven sebaceous 
tumour (ST) formation, supporting recent lineage tracing experiments, which identified HF bulge 
SCs as a cell-of-origin for STs. Mechanistically, mutant Lef1 induces DNA damage and interferes 
with SC-specific functions. In particular, mutant Lef1 blocks the Bcl2 response in HF bulge SCs 
and increased DNA damage induces apoptosis. To compensate the loss of bulge cells, proliferation 
was stimulated within the SC compartment, resulting in propagation of cells that escape normal 
cell cycle control. Furthermore, mutant Lef1 disturbs p53 response by antagonizing ATM-Chk2 
dependent stabilization of p53. Interestingly, manipulating p53 levels in SC-driven STs, revealed 
a new function of p53, determining ST growth, differentiation and progression. Thus our data 
demonstrate that normal SC regulation is disrupted by mutant Lef1, representing a new mechanism 
of tumour initiating events in tissue SCs and showing the importance of a tight control of these 
crucial SC-specific surveillance mechanisms. In addition, our results demonstrate for the first time 
a functional correlation of p53 levels and STs in vivo, proposing p53 as critical diagnostic marker 
for different types of STs.    
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Th1 immunity controls malignant transformation by preventing loss of differentiation
H Braumüller, T Wieder, E Brenner and M Röcken University Medical Center Tübingen, 
Tübingen, Germany
The risk of death from either melanoma or squamous cell carcinoma is directly linked to the tumor 
thickness at the time of excision. This raises the question, whether the cancer spreads because of 
the increased number of cancer cells or because of an altered, more de-differentiated biological 
behaviour. In addition, this raises also the question, wether cancer control by Th1-immune responses 
exclusively relies on cancer cell killing or also on other factors like induction of differentiation. To 
properly address these questions, we took advantage of a model cancer of the islets, where cancer 
cells first loose the capacity to respond to blood glucose and then the capacity to produce insulin 
while keeping the primitive differentiation marker synaptophysin. Immunofluorescence stainings 
revealed an oncogene-driven loss of differentiation antigens following an ordered fashion during 
tumor development. Small tumors expressed all 3 markers while large tumors still expressed synap-
tophysin and partially insulin but lost the glucose transporter 2 (GLUT2), the principal transporter for 
the transfer of glucose in pancreatic beta-cells, completely. Treatment with Th1 cells prevented the 
loss of both GLUT2 and insulin. Functional analysis of isolated cancer cells showed a loss of glu-
cose-induced insulin release whereas isolated beta-cells from Th1-treated mice normally responded 
to high glucose levels by releasing insulin. The preservation of the differentiation markers insulin and 
GLUT2 in Th1-treated mice was due to the TNF receptor 1 (TNFR1) as mice lacking TNFR1 rapidly 
lost the expression of GLUT2 and did not respond to glucose stress by releasing insulin any more. In 
conclusion, tumor-specific Th1 cells not only stop unrestricted tumor growth by controlling cancer 
cell growth but arrest malignant transformation by keeping the tumor cells in a differentiated state.   
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B cells Promote Tumor Immunity against B16F10 Melanoma
T Kobayashi,1 T Matsushita,1 Y Hamaguchi,1 M Hasegawa,2 M Fujimoto3 and K Takehara1 
1 Department of Dermatology, Institute of Medical, Pharmaceutical, and Health Sciences, 
Kanazawa University, Kanazawa, Japan, 2 Dermatology, University of Fukui, Fukui, Japan 
and 3 Dermatology, University of Tsukuba, Tsukuba, Japan
B cells are known to be critical mediators of tumor immunity; however, the mechanisms through 
which they exert this function remain unclear. B-cell linker protein (BLNK) is an essential com-
ponent of the B cell antigen receptor signaling machinery and is required for B cell development 
as evidenced by BLNK-deficient (BLNK-/-) mice, in which the development and function of B cells 
are severely impaired. In this study, we evaluated the role of B cells in the development of tumor 
immunity against B16F10 melanoma using BLNK-/- mice. B16F10 melanoma grew more aggressively 
in BLNK-/- mice resulting in a two-fold increase in tumor volume as compared to wild-type mice. 
As predicted, tumor-infiltrating B cell numbers were decreased in BLNK-/- mice. Paradoxically, 
tumor-infiltrating T cell numbers were decreased in BLNK-/- mice although inguinal lymph node T 
cell numbers were increased. Adoptive transfer of B cells from wild-type mice into BLNK-/- mice 
attenuated B16F10 melanoma growth with increasing numbers of B cells and T cells infiltrating into 
tumors. In addition, percentages of interferon-γ and tumor necrosis factor-α producing tumor-infil-
trating T cells were restored. Taken together, our study supports the concept that B cells enhance 
tumor immunity against B16F10 melanoma by promoting T cell infiltration into tumors and cytokine 
production within the tumor microenvironment.    
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Tumor cell-intrinsic PD-1 pathway effects promote Merkel cell carcinoma growth
C Posch,1 S Kleffel,1 MC Joubert,1 Q Zhan,2 S Fucaloro,1 M Thakuria,1 TS Kupper,1 
GF Murphy2 and T Schatton1 1 Dermatology, Brigham and Women’s Hospital, Boston, MA 
and 2 Pathology, Brigham and Women’s Hospital, Boston, MA
Merkel Cell Carcinoma (MCC) is a rare, but highly aggressive and therapy-resistant cancer of the skin. 
Recently, inhibitors targeting the programmed cell death-1 (PD-1) checkpoint pathway have shown 
remarkable clinical activity in patients with advanced-stage cancers of various etiology, including 
MCC. Similar to alternative checkpoint inhibitors, PD-1 therapy boosts antitumor immunity via 
immune cell-specific checkpoint blockade. However, PD-1 inhibitors have yielded response rates 
that markedly exceed those of alternative immunotherapies in MCC and other cancers, raising 
the possibility that additional mechanisms might contribute to its therapeutic efficacy. Here, we 
demonstrate PD-1 expression by established MCC lines and clinical tumor biopsies, and identify 
a critical role of MCC-intrinsic PD-1 signaling in tumor growth, including in the absence of a 
functional adaptive immune system. In four established MCC cell lines, MKL-1, MKL-2, MS-1, and 
WaGa, RT-PCR amplification and sequencing revealed expression of the full PD-1 (PDCD1) mRNA 
coding sequence and immunoblot analysis demonstrated PD-1 protein expression. Flow cytometric 
analysis showed PD-1 surface protein expression by 4/4 MCC lines and by CK20+CD45- tumor 
cells derived from clinical MCC specimens. PD-1 ligation on MCC cells induced pro-tumorigenic 
signaling downstream of the PD-1 receptor on MCC cells, which was blocked by antibodies to 
MCC-expressed PD-1. Consistently, in vivo administration of a PD-1 blocking antibody to highly 
immunocompromised NSG mice resulted in significant suppression of PD-1 receptor signaling and 
growth inhibition of human MCC xenografts, concomitant with binding of in vivo administered 
anti-PD-1 antibody to MCC target cells. Our results identify MCC-intrinsic PD-1 signaling as a novel 
tumor growth-accelerating mechanism, the blockade of which could enhance the clinical efficacy 
of PD-1 inhibitors in patients afflicted with this often-fatal malignancy.    
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MiR-203 is suppressed in poorly but not well-differentiated cutaneous squamous cell carci-
nomas and regulates the expression of MYC oncogene
W Lohcharoenkal,1 M Harada,2 J Lovén,3 NX Landén,1 M Ståhle,1 E Sonkoly,1 M Arsenian-
Henriksson,3 D Grandér2 and A Pivarcsi1 1 Unit of Dermatology, Karolinska Institutet, 
Stockholm, Sweden, 2 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 
Sweden and 3 MTC, Karolinska Institutet, Stockholm, Sweden
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent skin cancer and affects more 
than 500,000 new patients per year throughout the world. Recently, we and others observed that 
microRNA-203 (miR-203) is preferentially expressed in the skin and that it promotes differentiation 
of keratinocytes. Here we demonstrate that expression of miR-203 in cSCC correlates with the 
differentiation grade of tumors with being down-regulated in poorly but not in well-, or moderately 
differentiated cSCC. In vitro, miR-203 suppresses all important cancer phenotypes including cell 
proliferation, scratch-wound closure, cell migration and invasion and colony forming ability of SCC 
cells. In vivo, ectopic overexpression of miR-203 significantly suppressed primary tumor growth in 
SCC xenograft experiments. Mechanistically, the analysis of the transcriptome of cells with over-
expression of miR-203 identified a network of cancer-associated genes, which were suppressed 
by miR-203, one of which was c-MYC, an oncogene known to promote SCC progression. Using 
luciferase reporter assays we demonstrated a sequence-specific interaction between miR-203 and 
the 3’UTR of MYC transcript resulting in posttranscriptional silencing of c-MYC expression and 
that c-MYC protein levels were diminished in SCC transfected with miR-203 mimics. Highlighting 
the importance of c-MYC within the miR-203-regulated gene network, rescue experiments with 
the ectopic overexpression of c-MYC could revert the miR-203-induced growth arrest in SCC. In 
conclusion, our data establish an inverse correlation of miR-203 level with the differentiation status 
of SCC as well as demonstrate that miR-203 regulates the expression of cancer hallmarks in vitro and 
tumor growth in vivo. Deregulation of the miR-203/c-MYC axis may contribute to the progression 
of SCC and thus it may represent a target for cancer treatment.    
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Mechanisms regulating HPV8-mediated tumorigenesis
X Ding,1 T Lucas,1 G Marcuzzi,2 H Pfister2 and S Eming1 1 Department of Dermatology, 
University of Cologne, Cologne, Germany and 2 Institute of Virology, University of Cologne, 
Cologne, Germany
Beta human papillomaviruses (HPV) have been suspected to be carcinogenic in nonmelanoma skin 
cancers (NMSC), but the basis for potential viral contributions to these cancers is poorly understood. 
We previously developed a HPV8 transgenic mouse model, which recapitulates the HPV-induced 
SCC pathology. In nonviral preclinical models, VEGF-A has been identified as a critical regulator of 
NMSC. However, the role of VEGF-A in HPV-induced NMSC is not resolved, neither the question 
whether diverse cellular sources of VEGF-A may impact this process. In this study we dissected 
the contribution of epidermis- versus myeloid cell-derived VEGF-A in HPV8-mediated skin cancer 
using a combination of HPV8 transgenic mice and conditional gene targeting for VEGF-A. Here 
we show, that epidermis-specific deletion of VEGF-A results in complete abrogation of tumor ini-
tiation in HPV8 mice both spontaneous and under diverse tumor promoting conditions (UV light, 
skin wounding). In contrast, myeloid cell-derived VEGF-A is only critical in regeneration-induced 
tumorigenesis triggered by skin injury. Mechanistically, we show that blocking VEGFR2 inhibited 
injury-induced papilloma formation in HPV8 transgenic mice, indicating an important paracrine 
function of VEGF-A on tumor angiogenesis. Notably, papilloma-derived keratinocytes showed 
an upregulation of VEGFR1 and Nrp1 expression at the mRNA and protein level, suggesting the 
existence of an autocrine effect of VEGF-A on epidermal keratinocytes during tumorigenesis next 
to VEGF-A-mediated activities on angiogenesis. Taken together, here we provide novel mechanistic 
insights in distinct functions of epidermal- versus myeloid cell-derived VEGF-A in HPV8-mediated 
tumor development, which may have important implications for the prevention and treatment of 
HPV-mediated skin cancer.    
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Dysregulation of soluble adenylyl cycase leads to melanocyte transformation
CA Nardin,1 M Park,2 A Bacchiocchi,3 R Halaban3 and J Zippin4 1 Dermatologie, Centre 
Hospitalier Universitaire de Besancon, Besancon, France, 2 Dermatology, Albert Einstein 
College of Medicine, New York, NY, 3 Dermatology, Yale University, New Haven, CT and 4 
Meyer Cancer Center, Weill Cornell Medical Center, New York, NY
Most melanomas display an overactivation of the MAPK pathway resulting most commonly from 
activating mutations of BRAF (50%) and NRAS (20%). The MAPK pathway is subject to multiple 
forms of regulation. One example is the cAMP, protein kinase Adependent phosphorylation and 
inhibition of CRAF. cAMP which is synthesized by adenylyl cyclases which consist of two classes 
of enzymes, transmembrane adenylyl cyclases and the soluble adenylyl cyclase, is dysregulated 
in melanoma. sAC is downregulated in numerous cancers including melanoma and is mutated in 
about 10% of melanomas. In addition, sAC is differentially localized in benign versus malignant 
melanocytes suggesting that sAC may play a role in melanomagenesis. To investigate the role of 
sAC in melanocytes we established wildtype (WT) and sAC knockout (KO) immortalized mouse 
melanocyte cell lines. sAC KO cells exhibit a distinct cellular morphology as compared to WT 
melanocytes. sAC KO melanocytes exhibited an activation of both MEK and ERK, an altered cell 
cycle profile, and displayed a more active growth phenotype (pvalue < 0.05). Finally, only sAC 
KO cells were able to form colonies in soft agar suggesting that simple loss of sAC expression is 
sufficient to facilitate transformation of melanocytes (pvalue < 0.05). These results support previous 
data found in other cell type (fibroblasts) that sAC has a key role in the development of cancer. 
Current work is focused on establishing the mechanism of sACdependent MAPK regulation, and 
further confirmation of the role of sAC in melanomagenesis in vivo.    
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Attenuation of human SCC malignancy by introduction of reprogramming factors
M Takaishi,1 M Tarutani,1 J Takeda2 and S Sano1 1 Department of Dermatology, School of 
Medicine, Kochi University, Nankoku, Japan and 2 Department of Social and Environmental 
Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
Epithelial to mesenchymal transition (EMT) is the essential program for cancer cells to invade and 
metastasize. Interestingly, it was shown that mesenchymal to epithelial transition (MET), the reverse 
program of EMT, occurred in murine induced pluripotent stem cells (iPSCs) from fibroblasts by 
introduction of reprogramming factors. We asked whether MET occurred in cancer cells as well 
with the reprogramming factors and whether it attenuated malignant nature. The reprogramming 
factor genes (OCT4, SOX2, KLF4, MYC and LIN28) were introduced into human SCC cells having 
mesenchymal characters using a piggyBac transposon vector. The reprogramming factors-introduced 
(RFI) SCC cells acquired epithelial characters recognized by morphology and molecular markers. 
The RFI cells also showed reduced migration and invasion activities in vitro, suggesting that the 
enforced reprogramming led to attenuation of malignancy of SCC cells. To investigate the effect of 
reprogramming factors in vivo, we inoculated nu/nu mice with OSC-19 cells, a human oral SCC, 
since they frequently metastasize in the cervical lymph nodes when implanted into the tongue. RFI 
OSC-19 cells demonstrated MET with up-regulation of epidermal molecules in contrast to parental 
OSC-19 cells showing EMT. Transplanted RFI OSC-19 cells showed attenuated growth in the 
tongues and no metastasis to lymph nodes was found, when the parental OSC-19 cells metastasized. 
Collectively, the reprogramming factors could reduce malignant nature of cancer cells in vitro and 
in vivo through induction of MET. Therefore, the introduction of reprogramming factors may be 
relevant to a novel anticancer strategy.    
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Role of Xeroderma pigmentosum fibroblasts in squamous cell carcinoma cells invasion
SI Al-qaraghuli, S Rouanet, C Gagioli, J Albrengues, M Goncalves-Maia, T Magnaldo and 
Y Gache Institute for research on cancer and aging, Nice, France
Squamous cell carcinoma (SCC) is the most frequent metastatic skin cancer. The etiology of skin 
SCC is linked to exposure to genetic stress, notably ultraviolet radiation (UVR). Xeroderma pigmen-
tosum type C (XP-C) is a rare genetic disorder characterized by a severe susceptibility to particularly 
aggressive SCCs following minimal exposure to UVR, hence compromising the life expectancy 
of patients. XP-C cells are deficient in the nucleotide excision repair mechanism (NER) of DNA 
lesions introduced at bipyrimidine sequences upon UVR exposure. In addition, we reported that 
XP-C dermal fibroblasts constitutively expressed a phenotype resembling that of stromal fibro-
blasts associated to cancer cells (Carcinoma Associated Fibroblasts, CAFs) with accumulation of 
reactive oxygen species and over expression of matrix metalloproteinase 1. We further explored 
the phenotype of XP-C fibroblasts. We show here that they constitutively overexpress hepatocyte 
growth factor/scatter factor (HGF/SF). In organotypic skin cultures, XP-C fibroblasts promoted the 
invasion of SCC cells. Also, scratch healing of SCC cells was enhanced in culture supernatants of 
XP-C fibroblasts through a mitogenic effect connected to increased ratio of SCC cells in the G2-M 
phase of the cell cycle. Blockage of c-MET activation prevented invasiveness of SCC cells within 
dermal equivalent through inhibition of p38 activation by XP-C fibroblasts culture supernatants. 
Our data indicated for the first time that absence of XPC in fibroblasts leads to overexpression of 
cell growth stimulators such as HGF and other factors (MMP1) responsible for the formation of a 
microenvironment permissive towards SCC cells proliferation and invasion. Therapies targeting 
XP-C fibroblasts may be considered as a way to control cancer in XP patients as well as in patients 
from the general population suffering from aggressive cancers.    
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The role of argonaute protein 2 in cytokine-induced senescence of cancer cells
M Rentschler, Y Chen, H Braumüller, J Pahl, E Brenner, S Weidemann, T Wieder and 
M Röcken Dermatology, University Medical Center Tübingen, Tübingen, Germany
Overexpression of oncogenic HRAS (HRASG12V) permanently arrests cell division, a phenomenon 
named oncogene-induced senescence. Since oncogene-induced senescence also occurs in prema-
lignant lesions in vivo, it is now well accepted as an endogenous tumor suppressor mechanism. 
In previous studies, we show that adaptive immunity and the T helper cell 1 (TH1) cytokines 
interferon-gamma (IFN-gamma) and tumor necrosis factor (TNF) drive cancer cells into senescence. 
Cytokine-induced senescence (CIS) mainly depends on activation of the p16INK4a/Rb pathway, and 
consecutive inactivation of the E2F family of transcription factors. However, the exact regulatory 
mechanism remained enigmatic. As argonaute protein 2 (Ago2) in association with Rb corepresses 
E2F target genes, we analyzed its role in CIS. Treatment of different human cancer cell lines with 
IFN-gamma and TNF permanently stopped cell proliferation in the absence of cell death, and 
increased senescence-associated β-galactosidase activity. We then tested the expression and local-
ization of Ago2 protein after cytokine challenge using Ago2/Ki67 immunofluorescence staining. 
As expected, all cancer cells showed Ago2 expression independent of the culture conditions. Yet, 
following treatment with the cytokine cocktail, Ago2 translocated from the cytoplasm into the 
nucleus in Ki67-negative, non-proliferating cancer cells. Ago2 translocation occurred after 24 – 48 
h of treatment, and can thus be considered as an early event in cytokine-induced senescence. 
Furthermore, siRNA-mediated knockdown of Ago2 released the cancer cells from cytokine-induced 
growth arrest. Thus, CIS is an important tumor suppressor mechanism that permanently stops the 
proliferation of human cancer cells by an Ago2-dependent mechanism. As Ago2 translocated into 
the nucleus of non-proliferating cells, probably as a corepressor of the E2F/Rb complex, Ago2 
contributes significantly to senescence induction in human cancers.    
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Mast cell-derived vascular endothelial growth factor contributes to tumor growth
A Rabenhorst,1 S Leja,1 A Florin,2 A Förster,1 LC Heukamp,2 RT Ullrich,3 S Willenborg,1 
S Eming,1 R Büttner2 and K Hartmann1 1 Department of Dermatology, University of Cologne, 
Cologne, Germany, 2 Institute of Pathology, University of Cologne, Cologne, Germany and 3 
Clinic I of Internal Medicine, University of Cologne, Cologne, Germany
Mast cells (MC) actively participate in tumor growth by directly affecting proliferation and inva-
siveness of tumor cells or by indirectly regulating the tumor microenvironment. MC infiltrates have 
been correlated with tumor progression, prognosis and microvessel density in various neoplastic 
diseases. During tumor progression, an angiogenic switch causes formation of new vessels from 
existing vasculature. The best-studied inducer of angiogenesis is vascular endothelial growth factor 
(VEGF). To address the role of MC in tumor angiogenesis, we generated transgenic mice lacking 
mast cell-derived VEGF by crossing VEGFfl/fl mice to the Mcpt5Cre strain, which expresses Cre 
recombinase specifically in connective tissue type MC. Tumor growth of subcutaneously injected 
Lewis lung carcinoma cells (LLC) was significantly decreased in MC-specific VEGF knockout mice 
and in MC-deficient transgenic mice. Moreover, induced depletion of MC during tumor growth 
resulted in smaller LLC tumors. Tumor growth was also reduced by treating growing tumors with 
the anti-VEGF antibody bevacizumab. Furthermore, we investigated MC in different histological 
subtypes of human lung adenocarcinoma and found significantly increased numbers of MC. Patients 
with metastatic lung adenocarcinoma compared to non-metastatic carcinoma showed higher MC 
counts and higher numbers of degranulated MC, suggesting also enhanced MC activation. Taken 
together, our findings demonstrate that MC promote growth of murine LLC tumors and the metastatic 
potential of human lung adenocarcinoma. MC-derived VEGF may account for part of this effect. 
Hence, anti-VEGF antibodies may be a promising therapeutic approach in MC-associated tumors.   
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Virus -host interactome of oncoproteins and capsid proteins of Merkel cell polyomavirus
A Touze,1 N Jerome,1 M Samimi,1 Y Jacob,2 C Demeret2 and M Ferté Chaudoy1 1 University 
of Tours, Tours, France and 2 Institut Pasteur, Paris, France
The Merkel cell polyomavirus (MCPyV) is recognized as the etiologic agent of Merkel cell carci-
noma. However, the mechanisms leading to infection and the virus-induced tumorigenesis are 
poorly understood. Our work aims to identify the cellular partners of the MCPyV oncoproteins (Large 
T and small T antigens) and structural proteins (VP1, 2 and 3) to characterize its virhostome (virus-
host interactome). The identification of the interaction between the viral proteins and the cellular 
partners is accomplished by a yeast two hybrid system and then validated using a complementation 
assay in mammalian cells (HT-GPCA, High-Throughput Gaussiaprinceps Complementation Assay). 
The small T antigen was found to interact with the phosphatase protein PP2A involved in oncogenic 
signaling pathways. We have also demonstrated interactions between VP2 and various cellular 
proteins involved in intracellular trafficking, cell cycle regulation or the NFkB pathway. Biological 
effects of these interactions are being currently characterized in different cell lines. These results 
will improve our understanding of the biology of MCPyV and steps of virus-induced oncogenesis, 
as well as identification of potential therapeutic targets in Merkel cell carcinoma.    
113
Anti-tumor effect of an epithelial microRNA, miR-203, in melanoma 
W Lohcharoenkal, L Zhang, NX Landén, M Ståhle, L Girnita, E Sonkoly and A Pivarcsi 
Karolinska Institutet, Stockholm, Sweden
MiRNAs are a class of small non-coding RNAs which regulate gene expression at the post-transcrip-
tional level by binding to the 3’UTR of the target gene resulting in the mRNA cleavage or translation 
suppression. MiR-203 functions as a tumor suppressor in several cancer types. In this study, we 
investigated the potential of miR-203 to suppress cancer phenotypes in malignant melanoma. Using 
3 different melanoma cell lines (BE, DFB and SK-Mel-28), we demonstrated that overexpression 
of miR-203 could suppressed several important cancer phenotypes including cell migration, cell 
invasion and colony formation in these cell lines. Moreover, miR-203 markedly decreased the num-
ber of adhered cells on collagen-coated surface in adhesion assays. Since miR-203 overexpression 
had a strong effect on cell migration/invasion, we investigated its effect on epithelial mesenchymal 
transition (EMT) and observed the suppression on Twist, SNAI and SLUG expression in miR-203-
transfected melanoma cells. Among these deregulated genes, we identified SLUG, a member of the 
Snail family of C2H2-type zinc finger transcription factors as a direct target of miR-203. MiR-203 
inhibited SLUG expression on both mRNA and protein level. In addition to cell-intrinsic effects, 
miR-203 also could affect tumor-induced neo-angiogenesis as demonstrated by the reduced tube 
forming efficiency of conditioned medium from miR-203-transfected melanoma cells on HuVECS. 
These results indicate the potential of miR-203 in future RNA-based therapeutics in melanoma.   
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Characterisation of tumoral regulatory T cells demonstrates a role for OX40 in human cuta-
neous squamous cell carcinoma immunity
C Lai,1 S Cho,1 J Theaker,2 R French,3 M Glennie,3 A Al-Shamkhani3 and E Healy1 1 
Dermatopharmacology, University of Southampton, Southampton, United Kingdom, 2 
Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, 
United Kingdom and 3 Cancer Sciences, University of Southampton, Southampton, United 
Kingdom
Cutaneous squamous cell carcinoma (cSCC) has been reported as the most prevalent type of cancer 
with metastatic potential. Dysfunctional T cell immunity strongly promotes cSCC development, as 
evidenced by our previous results which demonstrated that cSCC Tregs suppressed tumoral CD4+ 
and CD8+ effector T cell proliferation. In this study the role of OX40, a T cell co-stimulatory receptor, 
in suppression of the cSCC tumoral immune response was investigated. Immunohistochemistry using 
archived paraffin-embedded primary cSCCs showed significantly more FOXP3+ Tregs in primary 
cSCCs which metastasised than those that did not metastasise (44.4% versus 20.5% of immune 
infiltrate respectively, n=35 and n=40 respectively, p<0.0001). Likewise, OX40 was detected in 
higher numbers of immunocytes in primary metastasising cSCCs than those in non-metastasising 
cSCCs (18.9% versus 12.1% of immune infiltrate respectively, p=0.0101). Immunofluorescence 
microscopy demonstrated the presence of OX40 predominantly on FOXP3+ Tregs in primary cSCCs, 
and flow cytometry confirmed higher frequencies of tumoral Tregs expressing OX40 than tumoral 
CD4+FOXP3- T cells and CD8+ T cells. In addition, OX40 was greater on tumoral Tregs than on 
FOXP3+ Tregs from peripheral blood and normal skin (p<0.0001 for all comparisons, n=17 tumours). 
Lymphocyte proliferation assays showed that addition of an OX40 agonist enhanced PHA-induced 
proliferation of FACS-sorted cSCC CD4+ T cells (mean increase in proliferation 74.9%, p=0.0098, 
n=10 primary tumours), with no increase in OX40 expression by non-Treg cells, consistent with 
OX40 agonism limiting the Treg suppressive effect. These results suggest that OX40 expressing 
tumoral Tregs, which accumulate in cSCCs and associate with subsequent metastasis, can form a 
potential immunotherapeutic target to augment tumoral effector T cell responses.    
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mGlu1 Receptors and Downstream Signal Transduction Proteins as Therapeutic Targets for 
the Treatment of Melanoma
T Gelb,1 S Pshenichkin,2 H Hathaway,2 I Brownell,1 B Wolfe2 and J Wroblewski2 1 
Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 
and 2 Department of Pharmacology and Physiology, Georgetown University, Washington, 
DC
The metabotropic glutamate 1 receptor (mGluR1) is a novel therapeutic target for the treatment of 
melanoma. Using receptor agonists and antagonists we assayed the pharmacological and signaling 
profiles of mGluR1 and their impact on melanoma growth. Glutamate increased the viability of 
mGlu1-expressing melanoma cell lines, and antagonism of mGluR1 slowed melanoma growth in 
vitro and in vivo. Interestingly, glutamate failed to increase phosphoinositide (PI) hydrolysis, demon-
strating that canonical, Gαq-dependent signaling is not responsible for glutamate-mediated growth in 
melanoma. Furthermore, quisqualate, which potently stimulates PI hydrolysis in mGlu1-expressing 
neurons, failed to stimulate both PI hydrolysis and viability in melanoma cells. Although mGluR1 
activation has been reported to increase cAMP formation, glutamate failed to increase cAMP levels 
in the melanoma cells tested, demonstrating that this cascade is not responsible for mGluR1-medi-
ated growth. Our laboratory previously identified a novel mGluR1-mediated, G protein-indepen-
dent signaling cascade that requires receptor internalization by dynamin. The dynamin inhibitor, 
dynasore, selectively blocked glutamate-increased viability, but only in melanoma cells expressing 
mGluR1. These results suggest that protein internalization is responsible for mGluR1-mediated 
increases in melanoma cell viability. Importantly, dynasore and mGluR1 antagonists each inhibited 
growth of both BRAF and NRAS mutated mGluR1-expressing melanoma cell lines. This suggests 
that mGluR1 supports melanoma growth independently of specific MAPK-activating mutations, and 
treatments targeting mGluR1 may complement kinase inhibitor therapy. Indeed, in a preliminary 
experiment, an mGluR1 antagonist decreased the viability of BRAF-inhibitor resistant melanoma 
cells. Further elucidation of downstream mGluR1 signaling proteins may help identify novel targets 
for the treatment of melanoma.    
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The epidermal polarity protein Par3 acts as non-cell autonomous suppressor of malignant 
melanoma
M Mescher,1 M Rübsam,2 P Jeong,1 M Kranen,1 J Landsberg,3 M Schlaak,2 C Mauch,2 
CM Niessen,2 T Tüting3 and S Iden1 1 CECAD, University of Cologne, Cologne, Germany, 2 
Department of Dermatology, University of Cologne, Cologne, Germany and 3 Department 
of Dermatology and Allergy, University of Bonn, Bonn, Germany
The Par3-aPKC-Par6 polarity complex controls a variety of polarization processes during develop-
ment and tissue homeostasis. We recently identified both pro-oncogenic and tumor-suppressive 
roles of Par3 in different epidermal tumors in mice. Here we report a novel non-cell autonomous 
function of Par3 in malignant skin cancer. Par3 loss in the epidermal environment (Par3eKO) led to 
elevated melanoma multiplicity and lung metastases in the HGF-Cdk4R24C mouse melanoma model, 
suggesting that polarity proteins modulate the cross-talk of keratinocytes (KCs) and melanocytes 
(MCs) to suppress melanoma. MCs cocultured with Par3-KO KCs showed increased proliferation, 
survival and dedifferentiation as compared to controls, changes also observed in vivo in Par3eKO 
mice. As this required the direct KC-MC contact, we asked for adhesion molecules involved. We 
detected distinct P-cadherin localization at KC-MC contacts, and inhibition of P- but not E-cadherin 
rescued MC differentiation and reversed the aberrant MC adhesion to Par3-KO KCs. Moreover, 
surface P-cadherin protein was elevated in Par3-KO KCs and cocultured MCs, suggesting that Par3 
controls P-cadherin stability and function. Aberrant P-cadherin-mediated adhesion upon Par3 loss 
may thus provide a permissive niche for MC transformation. In human melanoma, epidermal Par3 
expression negatively correlated with melanoma progression, whereas P-cadherin robustly local-
ized to heterologous KC-MC adhesions and was overexpressed in melanomas, indicating that this 
classical cadherin contributes to KC-MC cross-talk also in the context of human disease. Together, 
we show that communication of key skin-resident cell types engages a subset of classical cadherins 
controlled by epidermal polarity proteins, and identified Par3 as a novel non-cell autonomous 
tumor-suppressor of malignant melanoma.    
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AIM2 promotes progression of cutaneous squamous cell carcinoma
M Farshchian,1 L Nissinen,1 E Siljamäki,1 P Riihilä,1 A Kivisaari,1 M Kallajoki,4 R Grénman,3 
J Peltonen,2 S Peltonen1 and V Kähäri1 1 Department of Dermatology, University of Turku 
and Turku University Hospital, Turku, Finland, 2 Department of Cell Biology and Anatomy, 
University of Turku, Turku, Finland, 3 Otorhinolaryngology, Head and Neck Surgery, 
University of Turku and Turku University Hospital, Turku, Finland and 4 Department of 
Pathology, University of Turku and Turku University Hospital, Turku, Finland
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. Chronic 
inflammation is associated with progression of cSCC and patients with chronic inflammatory dis-
eases have higher risk of developing cSCC. The human IFN-inducible genes comprise absent in 
melanoma 2 (AIM2), IFN-inducible protein X (IFIX), IFI16, and myeloid nuclear differentiation 
antigen (MNDA). We have studied the role of AIM2 in the progression of cSCC. Analysis of the 
expression of human IFN-inducible genes in cSCC cells (n=8) and normal epidermal keratinocytes 
(n=5) revealed overexpression of AIM2 mRNA in primary (n=5) and metastatic (n=3) cSCC cell 
lines and cSCC tumors (n=6) compared with controls. Strong and moderate tumor cell specific 
cytoplasmic labeling of AIM2 was noted in human sporadic cSCCs (n=81), whereas the expression 
of AIM2 was mainly moderate in cSCC in situ (cSCCIS) (n=60) and low or absent in actinic keratosis 
(AK) (n=71) and normal skin (n=15). Analysis of the staining intensity revealed significantly stronger 
AIM2 staining in cSCC compared with cSCCIS, AK and normal skin (P<0.05). AIM2 knockdown 
inhibited proliferation, and invasion of cSCC cells and production of invasion proteinases MMP13 
and MMP1. Analysis of the gene expression profile following AIM2 knockdown revealed down-
regulation of cell cycle related genes CDK1, cyclin A and B. Knockdown of AIM2 potently delayed 
growth and inhibited vascularization of cSCC xenografts in vivo. Together, these findings provide 
evidence for the role of AIM2, an important inflammasome component, in the progression of cSCC 
and identify AIM2 as an attractive therapeutic target in these invasive tumors especially metastatic 
and unresectable cSCC.    
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The Effect of Topical Diclofenac 3% and Calcitriol 3mg/g on Superficial and Nodular Basal 
Cell Carcinoma: a Phase II, Randomized Controlled Trial.
T Brinkhuizen,1 K Frencken,1 P Nelemans,2 M Hoff,1 N Kelleners-Smeets,1 A Zur Hausen,3 
D Rennspies,3 V Winnepenninckx,3 M van Steensel1 and K Mosterd1 1 Dermatology, 
Maastricht University Medical Centre, Maastricht, Netherlands, 2 Epidemiology, Maastricht 
University Medical Centre, Maastricht, Netherlands and 3 Pathology, Maastricht University 
Medical Centre, Maastricht, Netherlands
Basal Cell Carcinoma (BCC) is the most common malignancy in Caucasians. Non-steroidal anti-in-
flammatory drugs and vitamin D derivatives are able to target signaling pathways activated in BCC. 
We investigated the efficacy of topically applied diclofenac sodium 3% gel, calcitriol 3μg/g ointment 
and a combination of both in patients with BCC. In this phase II, single-blind, randomized-controlled 
trial (NCT01358045), 128 eligible patients with a primary, histologically proven superficial (sBCC) 
(n=64) or nodular (nBCC) (n=64) received topical diclofenac, calcitriol, combination of both or 
no topical treatment (control group). After self-application twice daily under occlusion (8 weeks), 
tumors were excised. Primary outcome: post-treatment expression levels of proliferation (Ki-67) 
and anti-apoptosis (Bcl-2) markers. Secondary outcomes: histological clearance, adverse events, 
application-site reactions, patient compliance. Endpoints were available for 59 sBCC and 60 nBCC. 
In sBCCs, immunohistochemical analysis revealed a significant decrease in Ki-67 (p< 0.001) and 
Bcl-2 (p=0.001) tumor expression after treatment with diclofenac. Also, Ki-67 was significantly 
decreased after combination therapy (p=0.012). Complete histological tumor regression was seen 
in 64.3% (9/14) (P=0.0003) of sBCCs after diclofenac and 43.8% (7/16) (P=0.007) of sBCCs after 
combination therapy compared to 0.0% (0/16) of controls. No considerable changes were found 
in nBCCs. Application-site reactions were mostly mild to moderate. Our results suggest that top-
ical diclofenac is a promising new treatment for sBCC. Its mode of action differs from available 
non-invasive therapies, and thus has an additive value. Combination with traditional non-invasive 
treatments is an interesting topic for further research.    
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Anti-melanoma immunity and local clinical responses of stage III-IV melanoma patients 
treated with monobenzone and imiquimod; a phase 2a trial
H Teulings,1 E Tjin,1 K Willemsen,1 S van der Kleij,2 H Kemp,3 L Nieuweboer-Krobotova,4 
JA van der Hage,2 WJ van der Veen,4 GN Relyveld4 and RM Luiten1 1 Dermatology, 
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2 Surgical 
Oncology, NKI-AVL, Amsterdam, Netherlands, 3 Human Metabolism, University of Sheffield, 
Sheffield, United Kingdom and 4 Dermatology, NKI-AVL, Amsterdam, Netherlands
Development of vitiligo-like depigmentation in melanoma patients during immunotherapy is a 
favourable prognostic sign and indicates breakage of tolerance against melanoma antigens. We have 
developed monobenzone-imiquimod (MI) therapy that induces specific immunity against melano-
cytes and melanoma cells and inhibits melanoma growth in vivo. This phase 2a study evaluated 
the local clinical and systemic immunological effects of MI therapy in melanoma patients. Patients 
with stage III or IV melanoma with multiple non-resectable cutaneous metastases were treated with 
daily monobenzone cream and 3x/ week imiquimod applied locally to the cutaneous metastases and 
adjacent skin. Local tumor responses and the induction of local and systemic anti-melanoma immu-
nity were assessed after 12 weeks. 21 patients of 25 enrolled patients were evaluable for clinical 
assessment at 12 weeks. MI therapy was well tolerated. Partial regression of cutaneous metastases 
was observed in 8 patients and stable disease in 1 patient, which reached the statistical endpoint 
of treatment efficacy. Continued treatment in responding patients improved the clinical responses. 
Seven patients developed vitiligo-like depigmentation. Melanoma-specific CD8+T cell responses 
were induced in 17 patients of 19 patients tested and melanoma specific antibody responses in 
8 patients. These results indicate that targeting melanocytes directly by local skin application of 
low-cost and broadly applicable depigmenting agent monobenzone combined with imiquimod 
effectively induces systemic anti-melanoma immunity (both CD8+T-cell and antibody responses) 
leading to regression of cutaneous metastases in 35% of patients.    
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Analysis of melanoma development with the xeroderma pigmentosum model 
Y Gache,1 SI Al-qaraghuli,1 S Rouanet,1 M Goncalves-Maia,1 M Ohanna,2 C Bertolotto,2 
R Ballotti2 and T Magnaldo1 1 IRCAN - INSERM1081 - CNRSUMR7284, Nice, France and 
2 C3M, Nice, France
Our objectives are to study the mechanisms implicated in the development of human cancers among 
which squamous cell carcinoma (SCC), and malignant melanoma (MM) of the skin account for the 
most aggressive neoplasms. Increasing evidences support the idea that stromal cells, notably dermal 
fibroblasts, promote tumor cells aggressiveness and invasive capacities. Xeroderma pigmentosum 
(Group C, XP-C) is a rare genetic disorder characterized by defective nucleotide excision repair 
(NER) of UV-induced DNA lesions and severe proneness toward aggressive skin cancers. To shed 
light on the agressiveness of XP skin cancers, we hypothesized that XP-C fibroblasts could play a 
prominent role through pejorative stroma-cancer cells interactions. We found that XP-C fibroblasts 
present features of cancer associated fibroblasts (CAF) towards epidermal keratinocytes in absence 
of genotoxic stress. Here, we analyzed the capacity of XP-C fibroblasts to promote migration and 
invasion of cells derived from human MM. Our results show that the secretome of XP-C fibro-
blasts elicited migration and invasion of the non-tumorigenic Mel501 melanoma cells in vitro. 
Treatment of Mel501 cells with culture supernatant of XP-C fibroblasts but not of their genetically 
counterparts was sufficient to promote tumorigenesis in mice. Screening of molecules secreted by 
XP-C fibroblasts identified Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and CXCL12/SDF1 as 
potential pro-invasive/tumorigenic protagonists. Mel501 cells cultured in culture media conditioned 
by primary XP-C fibroblasts showed activation of the c-Met receptor and of the downstream p38 
and JNK effectors, as well. Depletion of HGF in XP-C culture media conditioned by XP-C fibro-
blasts supressed c-Met activation. Our studies demonstrate for the first time that XP-C fibroblasts 
play a decisive role in melanoma progression and identify factors responsible for the formation of 
a permissive microenvironment.    
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STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor 
immunity.
O Demaria,1 N Gestermann,1 J Di Domizio,1 O Gaide,1 D Speiser,3 RL Modlin2 and 
M Gilliet1 1 Dermatology, CHUV, Lausanne, Switzerland, 2 Dermatology, David Geffen 
School of Medicine at University of California, Los Angeles, CA and 3 Ludwig Cancer 
Research, Lausanne, Switzerland
Spontaneous CD8 T cell responses occur in growing melanoma but are usually poorly effective. 
Understanding the molecular and cellular mechanisms that drive these responses is of major interest 
as they could be exploited to generate a more efficacious antitumor immunity. As such, STimulator 
of INterferon Genes (STING), an adaptor molecule involved in cytosolic DNA sensing, is required 
for the induction of anti-tumor CD8 T responses in mouse models of cancer. Here, we find in a 
mouse model of melanoma that activation of STING by intratumoral injection of cyclic GMP-AMP 
(cGAMP), potently enhanced anti-tumor CD8 T responses leading to growth control of injected and 
contralateral tumor. The ability of cGAMP to trigger anti-tumor immunity was further enhanced by 
the blockade of both PD1 and CTLA-4. The STING-dependent anti-tumor immunity, either induced 
spontaneously in growing tumors or induced by cGAMP injection was dependent on type I IFNs 
produced in the tumor microenvironment. In response to cGAMP injection, both in the mouse 
melanoma model and an ex vivo model of cultured human melanoma explants, the principal 
source of cGAMP-induced type I IFN was not dendritic cells, but instead endothelial cells. These 
data identify an unexpected role of the tumor vasculature in the initiation of CD8 T cell antitumor 
immunity and also provide a new cell target for immunotherapy in the treatment of melanoma.   
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Tumor cell lineage-specific analysis reveals new signatures for understanding melanoma 
biology
F Rambow,1 B Job,2 V Petit,1 F Gesbert,1 V Delmas,1 G Meurice,2 P Dessen,2 R Cornell,3 
A Sarasin2 and L Larue1 1 Institut Curie, Orsay, France, 2 Gustave Roussy, Villejuif, France 
and 3 University of Iowa, Iowa City, IA
Molecular signatures specific to particular tumor types are urgently required for the design of 
treatments for resistant tumors. However, it remains unclear whether tumors and the corresponding 
cell lines used for drug development share such signatures. We developed SCA (similarity core 
analysis), an unsupervised computational framework for extracting core molecular features com-
mon to tumors and cell lines. We applied SCA to mRNA and miRNA expression data from various 
sources, comparing melanoma cell lines and metastases. The signature obtained was associated 
with phenotypic characteristics in vitro and the core genes CAPN3 and TRIM63 were implicated in 
melanoma cell migration and invasion. About 90% of the genes in the melanoma signature may be 
regulated by an intrinsic network of transcription factors governing neural development (TFAP2A, 
DLX2, ALX1, MITF, PAX3, SOX10, LEF1 and GAS7) and three miRNAs (211-5p, 221-3p, 10a-5p). The 
SCA signature effectively discriminated between two subpopulations of melanoma patients differing 
in overall survival. It also correctly classified MEKi and BRAFi resistant and sensitive melanoma cell 
lines. SCA could be used on other tumor cell types.    
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Versican up-regulation in Sézary cells
K Fujii,1 M Karpova,1 K Asagoe,1 O Georgiev,2 T Kanekura,3 K Iwatsuki,4 R Dummer1 and 
M Urosevic-Maiwald1 1 Department of Dermatology, University Hospital Zurich, Zurich, 
Switzerland, 2 Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland, 
3 Department of Dermatology, Kagoshima University Graduate School of Medical and 
Dental Sciences, Kagoshima, Japan and 4 Department of Dermatology, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Sézary syndrome (SS) is a leukemic variant of cutaneous T cell lymphoma, whose etiology is 
still largely unknown. To investigate the pathology of SS, we performed transcriptome analysis of 
clonal T cells (Sézary cells: SC) obtained from five patients with SS, and identified that versican, 
an extracellular matrix proteoglycan, was the highest upregulated gene in SC. Furthermore, we 
identified that Versican isoform V1 was the most commonly up-regulated isoform in SCs in both 
mRNA and protein levels. To identify the functional role of versican V1 in SC, we established stably 
versican V1-overexpressed cell lines from 2 CTCL cell lines, Myla and SeAx. Both cell lines formed 
clusters, while the sizes from V1-transfected cells were significantly reduced compared to MOCK. 
Migration activities were significantly increased in both V1-transfected cells, and those effects 
were diminished by an inhibitor of versican, hyaluronidase. Versican V1-overexpression exerted 
an inhibitory effect on cell proliferation, partially by promoting activation-induced cell death. 
Furthermore, V1-overexpression in lymphoid cell lines increased their sensitivity to doxorubicin 
and gemcitabine. In conclusion, we confirm versican as one of the overexpressed genes in SS and 
describe its effects on the biology of SCs. Although versican overexpression confers lymphoid cells 
with the enhanced migratory ability, it also makes them more sensitive to activation-induced cell 
death and some chemotherapeutics, which could be exploited further for therapeutic purposes.   
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Topical administration of imiquimod modifies the profiles of tumor-associated macrophages 
in B16F10 melanomas.
T Fujimura, S Furudate, Y Kambayashi, A Kakizaki and S Aiba Department of Dermagtology, 
Tohoku University Graduate School of Medicine, Sendai, Japan
Tumor-associated macrophages (TAMs) are immunosuppressive cells that play roles in maintaining 
the tumor microenvironment through various mechanisms. Since TAMs produce various chemokines 
to recruit other immunosuppressive cells such as regulatory T cells (Tregs) and circulating immature 
myeloid cells, TAMs could be a target for immunotherapies. Imiquiomod (IQM) displays antitumor 
effects through Toll like receptor-7 (TLR-7). As a TLR-7 agonist, IQM stimulates innate immune 
cells, including macrophages. The purpose of this study was to elucidate the effects of IQM on the 
tumor microenvironment using the B16F10 melanoma model. B16F10 melanoma cells (2 x 105 
cells/ mouse) were subcutaneously injected into C57BL/6 mice, and when the tumor had reached 
5mm in diameter, we administered IQM topically. The topical administration of IQM significantly 
decreased the mRNA expression of Tregs-related chemokines (CCL17, CCL22) and increased the 
expression of cytotoxic molecules (granzyme B, perforin) in the tumor. In parallel with the mRNA, 
flow cytometry analysis revealed that IQM decreased Tregs and increased CD8+ cells in the tumor. 
Moreover, to validate the production of chemokines, we isolated CD11b+ cells by MACS, analyzed 
the chemokine production and confirmed the decrease of CCL22 in the IQM-treated group. To 
further investigate the immunomodulatory effects of IQM on circulating CD11b+ myeloid cells, we 
isolated CD11b+ cells from spleen. In parallel with CD11b+ cells from the tumor, IQM suppressed 
the production of CCL22 from splenic CD11b+ cells through TLR7 signaling. Moreover, these splenic 
CD11b+ cells from the IQM-treated group increased the production of IFN-γ and suppressed the 
B16F10 melanoma growth in vivo. Our present data suggest one of the possible mechanisms of the 
anti-tumor immune response against B16F10 melanoma by IQM through TAMs.    
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4-1BB activation enhances in vitro tumoral T cell function in cutaneous squamous cell 
carcinoma
C Lai,1 S Cho,1 J Theaker,2 R French,3 M Glennie,3 A Al-Shamkhani3 and E Healy1 1 
Dermatopharmacology, University of Southampton, Southampton, United Kingdom, 2 
Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, 
United Kingdom and 3 Cancer Sciences, University of Southampton, Southampton, United 
Kingdom
Co-stimulatory and inhibitory molecules play important roles in promoting or abrogating T cell 
responses. 4-1BB, a TNF receptor superfamily member, can amplify T cell responses whereas 
CTLA-4 is a negative regulator of T cell activation. As T cells are key contributors to anti-tumour 
immunity, we investigated the role of 4-1BB and CTLA-4 on tumoral T cell function in cutaneous 
squamous cell carcinoma (cSCC). Flow cytometric and immunofluorescence characterisation of 
T cells from human primary cSCCs showed large numbers of T lymphocytes predominantly in a 
peritumoral distribution within cSCCs, with the majority expressing CLA and/or CCR4 and situated 
close to E-selectin+ vasculature within the cSCC stroma. 11.0% of the tumoral immune infiltrate 
comprised Tregs (n=24 tumours), with flow cytometry showing 4-1BB on higher frequencies of 
tumoral CD4+FOXP3+ Tregs (12.6%) than CD4+FOXP3- (0.8%) and CD8+ T cells (1.2%), p<0.01 
for both comparisons, n=9 tumours. In addition, a greater proportion of cSCC Tregs were 4-1BB+ 
than Tregs from peripheral blood (1.4%) and normal skin (5.2%), p<0.01 for both comparisons. 
Whereas CTLA-4 was present on the cell surface in 18.0% of cSCC Tregs (n=6 tumours), CTLA-4 was 
expressed intracellularly by most Tregs (87.9%, n=10); this compared with 33.6% of CD4+FOXP3- 
T cells and 17.6% of CD8+ T cells, p<0.0001, n=10 tumours. Addition of agonistic anti-4-1BB 
antibody increased tumoral CD4+ T cell proliferation (48.7% increase, p=0.0029, n=11 tumours). 
However, addition of an anti-CTLA-4 neutralising antibody produced no significant effect on cSCC 
CD4+ T cell proliferation (n=9 tumours). These results indicate that 4-1BB activation enhances 
tumoral T cell function, highlighting 4-1BB agonism as a potential therapeutic strategy requiring 
further investigation in cSCC.    
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Human Constitutive Photomorphogenic Protein down-regulation modulates cancer-relevant 
gene expression in keratinocytes and sensitizes the cells to cisplatin
B Fazekas,1 MP Carty,2 I Németh,1 F Nagy,3 L Kemény,1 É Ádám3 and M Széll4 1 Department 
of Dermatology, University of Szeged, Szeged, Hungary, 2 Centre for Chromosome Biology, 
School of Natural Sciences, National University of Ireland, Galway, Ireland, 3 Institute of 
Plant Biology, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, 
Hungary and 4 Department of Medical Genetics, University of Szeged, Szeged, Hungary
The Human Constitutive Photomorphogenic Protein (huCOP1) is an E3 ligase and promotes ubiqui-
tin-dependent protein degradation. Initial studies have pointed at the possible roles for mammalian 
COP1 in carcinogenesis. We have previously demonstrated that huCOP1 is expressed in human 
keratinocytes and represses the p53-dependent tumor suppression, therefore emerges as a potential 
target molecule for non-melanoma skin cancer (NMSC). To define the role of huCOP1 in the tumour-
genesis, we characterized the altered signal transduction processes in human keratinocytes after 
the stable siRNA-mediated silencing of huCOP1. Real-time RT-PCR array revealed a transcriptional 
regulatory role for huCOP1 in the cancer-relevant networks in keratinocytes. Since the expression of 
the investigated genes was mainly upregulated after the silencing of huCOP1, we hypothesize that 
huCOP1 is a repressor of these networks. We showed that huCOP1 is implicated in the regulation 
of the MutS homolog 2 (MSH2) protein level in human keratinocytes. Many anticancer agents 
- including cisplatin - induce interstrand crosslinks (ICLs) in DNA, and mismatch repair (MMR) 
proteins (such as MSH2) have a role in the maintenance of genomic integrity. We demonstrated that 
silencing of huCOP1 sensitizes cells to the ICL-inducing agent cisplatin. The results provide new 
insights into the cellular pathways that mediate ICL repair in human cells induced by one class of 
DNA damaging agents widely used in cancer treatment, included in the NMSC.    
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Secretion of Chemerin from Senescent Human Dermal Fibroblasts Promotes Motility of Cuta-
neous Squamous Carcinoma Cells
V Farsam,1 A Basu,1 T Lucas,2 S Kochanek,2 M Wlaschek1 and K Scharffetter-Kochanek1 1 
Deapartment of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany and 2 
Department of Gene Therapy, University of Ulm, Ulm, Germany
The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing worldwide and dra-
matically rises with age. Recent evidence suggests that both accumulation of mutations as well as 
senescence-associated pro-oncogenic changes in tissue microenvironment contribute to the age-re-
lated increase in cancers. Accumulation of senescent fibroblasts releasing the senescent-associated 
secretory phenotype (SASP) is proposed to promote tumor progression and metastasis. However, 
the mechanisms underlying SASP-induced tumor progression of cSCC are not fully understood in 
sufficient molecular details. We identified that both the transcript and protein level of the chemo-
attractant Chemerin/Retinoic acid receptor responder protein 2 (RARRES2) were augmented in 
senescent fibroblasts compared to young fibroblasts. Enhanced concentrations of Chemerin were 
detected in human dermal fibroblasts of skin sections of old compared to young individuals as 
shown with immunofluorescence staining. Notably, Chemerin receptors CCRL2 and GPR-1, but 
not CMKLR1, were highly expressed in SCC lines compared to normal keratinocytes as shown with 
RT-qPCR and western blot analysis and confirmed with immunostaining of skin biopsies in situ 
in patients suffering from SCC. The paracrine SASP effect of senescent fibroblasts and Chemerin 
on the motility of SCC lines was studied using an in vitro Transwell migration assay. Conditioned 
media (CM) derived from senescent fibroblasts significantly increased the migration of SCC lines 
in comparison to young fibroblast CM. Interestingly, Chemerin enhanced the migration of SCC 
lines in a concentration dependent manner, which was mediated through the activation of the 
mitogen-activated protein kinase (MAPK) signaling pathway. Taken together, our results suggest that 
the contribution of senescent fibroblast in ageing stroma assists cSCC progression with Chemerin 
being a prime mediator.    
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JunB and its role in cytokine-induced cancer cell senescence
N Simon, R Seeger, T Wieder, J Bauer, H Braumüller and M Röcken Dermatology, University 
Medical Center Tübingen, Tuebingen, Germany
Tumor immunotherapy has recently become highly relevant for treatment of melanoma and 
other cancers. Interestingly, immunotherapy does not always lead to cancer cell apoptosis or kill-
er-cell-mediated killing but to stable growth arrest. This stable growth arrest, also known as senes-
cence, can be induced by the Th1 cytokines interferon gamma (IFNgamma) and tumor necrosis 
factor alpha (TNFalpha) in vitro and in vivo. Previous data showed an upregulation of the tumor 
suppressor gene p16INK4a, but the exact molecular pathway, by which cellular senescence is 
induced, is unknown. A possible candidate is JunB. This transcription factor is known as a target 
of the TNF signaling pathway, but an interaction between JunB and the p16INK4a promoter is 
yet unknown especially in the context of cytokine-induced senescence. Furthermore, it is unclear 
whether JunB can bind directly to the p16INK4a promoter or if it might be associated in a protein 
complex, for example AP-1. In order to investigate this signaling pathway in detail, we performed 
chromatin immunoprecipitation (ChIP) assays using cell lines isolated from the pancreas of RIP-Tag2 
mice. In this mouse model, the SV40 large T antigen 2 (Tag2) is expressed under the rat insulin 
promoter (RIP). This causes an inhibition of p53 and Rb1 exclusively in the Langerhans islets cells 
leading to a multistage carcinogenesis. First data show a translocation of JunB from the cytoplasma 
into the nucleus after cytokine treatment. In addition, an upregulation of JunB is observed on pro-
tein level, starting 4h after cytokine treatment and increasing up to 24h. Furthermore, preliminary 
ChIP data suggest a binding of JunB to the JunB promoter after 72h of stimulation, indicating an 
autocrine loop of JunB. Taken togheter, our findings suggest a role of JunB in the early phase of 
cytokine-induced senescence. In future studies, we will investigate whether JunB, probably as a 
part of a protein complex, interacts with the promoter of p16INK4a.    
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Basal cell carcinoma and inflammation: role of the Gadd45b gene 
M Maturo, C Pellegrini, D Verzella, C Martorelli, M Fischietti, A Piccioni, E Alesse, 
F Zazzeroni and M Fargnoli Biotechnological and Applied Clinical Sciences, University of 
L’Aquila, L’Aquila, Italy
Non-melanoma skin cancer (NMSC), i.e. basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC), are the most common malignant neoplasias in white individuals with ultraviolet exposure 
being the main risk factor. Growth arrest DNA damage-inducible gene 45b (Gadd45b) is a pivotal 
player in the NF-kB pathway involved resistance to apoptosis and in cancer-related inflammation. 
To test if Gadd45b is involved in BCC carcinogenesis, we investigated the expression level of 
Gadd45b in skin biopsy specimens of 20 BCCs and in normal skin of 5 volunteers as control 
using Real-time PCR and immunohistochemistry (IHC). In the same samples, levels of IL-17 and 
IL-23 inflammatory cytokines were also evaluated and correlated with Gadd45b expression. We 
found a statistically significant increase of Gadd45b mRNA in BCC versus normal skin (p<0.05). 
Gadd45b expression was increased both in nodular (p<0.05) and superficial (p<0.01) BCC. IL-23 
mRNA expression levels were 18-fold increased in BCCs as compared to normal skin (p<0.0001) 
while inconsistent data were obtained for IL-17 expression. Interestingly, we observed a positive 
correlation between mRNA expression of Gadd45b and of both IL23 and IL17 [Pearson coefficient 
r=0.55 (p=0.0091) and r=0,9647 (p= p<0.0001), respectively]. To determine which cells in tumor 
samples overexpress Gadd45b, IHC analysis of Gadd45b confirmed molecular data revealing a 
prevalent Gadd45b expression in inflammatory cells than in tumor cells and a positive correlation 
between IL-17 and IL-23 expression and the peritumoral inflammatory infiltrate. These results suggest 
a possible involvement of the NF-kB-Gadd45b cascade in BCC pathogenesis.    
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Epidermal Rac1 protects from UV induced skin carcinogenesis
J Deshmukh and I Haase Department of Dermatology, University of Cologne, Cologne, 
Germany
Non-melanoma skin cancer is the most common skin cancer in the fair skinned population. Over-
expression and increased activity of the small Rho GTPase Rac1 has been linked to squamous cell 
carcinoma of the epidermis and mucosa in humans. Targeted deletion of Rac1 or inhibition of Rac1 
activity in epidermal keratinocytes reduced skin tumor formation in a chemical skin carcinogenesis 
mouse model. However, a potential role of Rac1 in UV light induced skin carcinogenesis has not 
been investigated so far, solar UV radiation being an important carcinogen to the skin. To investigate 
this, we deleted Rac1 or modulated its activity in mice with transgenic expression of the complete 
early region of Human papilloma virus type-8 (HPV-8) in epidermal keratinocytes. In accordance 
with previous studies our data show that inhibition or deletion of Rac1 results in reduced papilloma 
formation upon UV irradiation, whereas constitutive activation of Rac1 dramatically increases papil-
loma frequency in these mice. Surprisingly, however, we observed that, in contrast to control mice, 
the majority of mice with epidermis specific Rac1 deletion developed squamous cell carcinomas 
upon chronic UV irradiation. Taken together, our data provide first direct evidence for a role of 
Rac1 in the suppression of UV induced skin carcinogenesis.    
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Detection of BRAF mutations in the plasma of metastatic melanoma patients 
AC Knol,2 A Vallée,1 E Varey,3 J Nguyen,4 G Herbreteau,1 S Théoleyre,1 A Khammari,3 
MG Denis1 and B Dréno3 1 Plateforme de Génétique des Cancers, Nantes, France, 2 
Laboratoire d’immuno-dermatologie, CHU HOTEL DIEU, CRCNA, Inserm U892, CNRS6299, 
Nantes, France, 3 Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, Nantes, 
France and 4 PIMESP, Nantes, France
Mutant BRAF DNA can be detected in plasma of melanoma patients bearing a mutation in their 
tumor. Circulating DNA is a promising non-invasive tool for cancer monitoring. The main objective 
of our work was to investigate the relationship between mutant BRAF DNA in plasma and clinical 
response. Forty stage IV patients with a mutated BRAF melanoma (31 V600E, 7 V600K, 1 V600R 
and 1 V600D) were included prior to any treatment and blood was then collected each month for 
a mean duration of 7.5 months (up to 22 months). DNA was extracted from 0.8ml EDTA plasma 
and mutant DNA was detected using allele specific PCR (Therascreen RGQ kit, Qiagen). Before the 
beginning of any treatment (D0), the corresponding BRAF mutation was detected in 21 out of the 30 
evaluable plasma samples (70% sensitivity). At D0, we observed a strong correlation between the 
presence of circulating mutated DNA and overall survival (OS) (p=0.002). Interestingly, the number 
of metastatic sites correlated with the presence of circulating mutated DNA (p=0.017). Finally, 
the presence of circulating mutated DNA did not correlate with gender, age, breslow thickness or 
primary tumor localization. Concerning the clinical follow-up, we observed a correlation between 
the group of responders defined as complete response (CR) + partial response (PR) +/- stabilization 
(S) and the presence of circulating mutated DNA (p<0.01). We also report a strong correlation 
between the presence of circulating mutated DNA and OS (p=0.004) and with the period between 
lymph node involvement and cutaneous or visceral metastases (p=0.044). These results suggest that 
plasma DNA is an interesting alternative source of DNA to detect BRAF mutations before treatment 
and that detection of mutant BRAF in plasma is associated to a reduced OS in melanoma. Fundings 
: Supported in part by a grant from Roche    
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Squamous Cell Carcinoma progression and Laminin 332
M Caley,1 V Martins,1 S Marsh,1 K Moore,2 M Lashari,1 MJ Donaldson,3 J Marshall2 and 
E O’toole1 1 Centre for Cell Biology and Cutaneous Research, Barts and the London SMD, 
London, United Kingdom, 2 Barts Cancer Institute, Barts and the London SMD, London, 
United Kingdom and 3 Stiefel, a GSK company, Uxbridge, United Kingdom
The role of Laminin 332 in tumour development is poorly understood. It has been identified as both 
vital for tumour progression and to act as a potent tumour suppressor. Analysis of SCC tumours and 
cell lines using Laminin 332 chain specific antibodies identified a link between tumour progression 
and reduced expression of individual laminin chains. To investigate the role of laminin 332 in SCC 
further we generated stable knockdowns (KDs) of each Laminin 332 chain (LamA3, LamB3 & LamC2) 
in cutaneous SCC cell lines. Using these cells we studied their role in cell attachment, motility, in 
vitro and in vivo invasion, integrin expression, cellular signalling and global gene expression using 
RNA-seq. We identified distinct phenotypic and genotypic changes in each of our laminin chain 
KDs. Changes in cell attachment, motility and invasion were seen in vitro. The KD of LamA3 and 
LamC2 reduced attachment while increasing motility and invasion whereas no increase in motility 
or invasion were seen with KD of LAMB3. Distinct patterns of invasion were seen for each KD in 
vivo in a murine xenograft model with increased invasion seen with KD of LamA3 and LamC2. 
KD of LamA3 and LamC3 increased EMT in vivo with increased Vimentin and Twist and loss of 
E-Cadherin. The KD of LamB3 was characterised by increased differentiation in vivo with increased 
Keratin 10 and involucrin. Laminin332 binds to integrins α3β1 and α6β4. We investigated integrin 
expression using FACS and observed increased β1 integrin with KD of LamA3 and LamC2 and 
increased α6 with KD of LamA3 and LamB3. Downstream signalling pathways were also altered in 
a chain specific manner with alterations in FAK/Rac/ROCK signalling. RNA-seq analysis identified 
overrepresented genes involved in motility, invasion and cytoskeletal remodelling in the invasive 
knockdowns which were confirmed by QPCR and western blotting. These findings highlight the 
importance of each laminin 332 chain individually in SCC invasion.    
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Brimonidine treatment delays skin tumor development and decreases epidermal hyperplasia 
and keratinocyte proliferation in UV-exposed hairless mice
C Nonne,1 G Feraille,1 G Bouvier,1 D Learn,2 B Ruty1 and E Vial1 1 Galderma RD, Sophia 
Antipolis, France and 2 Preclinical Services, Charles River Laboratories, Horsham, PA
Brimonidine tartrate is an α2A-adrenergic receptor agonist and is the active ingredient of Mirvaso® 
gel. Mirvaso® is approved in the US and EU for the topical treatment of facial erythema of rosacea. 
We evaluated the protective effect of brimonidine tartrate against skin damages induced by UVB 
exposition in two types of in vivo experiments: i) an acute model of UVB-induced proliferation of 
basal keratinocyte and epidermal hyperplasia in hairless mice. In this model, mice are exposed to 
120 mJ/cm2 of UVB irradiation either 1 hour after a first topical treatment of brimonidine (0.2% or 
2%) or immediately before. Brimonidine is then re-applied at 23h and 46h and skin sampling is 
performed at 48h after UVB exposure ii) a mouse carcinogenesis model induced by chronic UV 
irradiations over a 40 weeks period, followed by 12 additional weeks of observation, in which 
brimonidine is topically applied at different doses on a daily basis. In the acute model, brimonidine 
at 2% applied before or after UVB on hairless mice decreased epidermal hyperplasia by 23% and 
32% and keratinocyte proliferation by 59% and 64%, respectively. In the photocarcinogenesis 
model, a marked and dose-related protective effect of brimonidine from 0.18% to 2% against 
UVR-induced skin damages was observed. These protective effects consisted of decreased skin 
tumor development (increased median time to tumor ≥1 mm, decreased tumor yield and tumor 
incidence) and decreased incidence of the photo damage-related clinical signs on the skin (ery-
thema, flaking, wrinkling and skin thickening). Overall, these studies demonstrated that brimonidine 
topical treatment has anti-tumoral properties in mice that could in part be explained by an ability to 
decrease the UVB-induced proliferation of keratinocytes. Our results suggest new therapeutic uses 
of brimonidine for chemoprevention of hyperproliferative epidermal disorders, of UV-photodamage 
and/or predisposition to cutaneous Actinic Keratosis or Squamous Cell Carcinoma.    
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Epigenetic regulation of epithelial-mesenchymal transition in squamous cell carcinoma of 
the skin
H Fujiwara Dermatology, Uonuma Institute of Community Medicine, Minamiuonuma, Japan
In the course of invasion and metastasis, cancer cells, including squamous cell carcinoma of the 
skin (SCC), acquire the phenotypic change to loose the intercellular connections and to migrate in 
surrounding tissues. This phenotypic change, epithelial-mesenchymal transition (EMT), is charac-
terized by decreased E-cadherin and increased N-cadherin expression (cadherin switching), loss of 
desmoplakin expression, and aberrant expression of vimentin, the mesenchymal type intermediate 
filament. To elucidate the mechanism of EMT in SCC, E-cadherin, N-cadherin desmoplakin, and 
vimentin mRNA and protein expression were examined. Since the gene promoter of above four pro-
teins possess CpG islands, I also studied the methylation state of their promoter regions by means of 
methylation-specific PCR, combined bisulfite restriction analysis (COBRA), and methylation detec-
tion-in situ hybridization (MDISH). The loss of E-cadherin was observed in all the SCC, regardless 
of invasive or early, non-invasive lesions. The DNA methylation of CDH1/E-cadherin was detected 
in all the SCC. Also with MDISH the promoter methylation of CDH1/E-cadherin was observed in 
entire SCC regardless of invasive or non-invasive lesions. On the contrary desmoplakin expression 
was lost only in the deep invasive lesion. DSP/desmoplakin DNA methylation was detected in a 
fraction of DNA samples in methylation-specific PCR and COBRA. DSP methylation was detected 
in a small number of invasive tumor cells with MDISH. N-cadherin and vimentin proteins were 
aberrantly expressed in invasive tumor cells. CDH2/N-cadherin and VIM/vimentin promoters were 
unmethylated in general. Only a few cases possessed methylated promoter DNA. The promoter 
methylation of CDH1/E-cadherin and DSP/desmoplakin resulted in decreased expression of their 
proteins in invasive SCC. Since CDH2/N-cadherin and VIM/vimentin promoters were unmethylated 
in general, the aberrant expression of these protein would be regulated through the other mechanism 
than promoter DNA methylation.    
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Non-invasive three-dimensional diagnostic approach to extramammary Paget’s disease by 
two-photon microscopy
T Murata, T Honda, Y Miyachi and K Kabashima Dermatology, Kyoto University, Kyoto, 
Japan
Extramammary Paget’s disease (EMPD) is one of the most intractable malignant tumors of the skin, 
and the information of three-dimensional (3D) distribution of Paget cells is unknown. Currently, 
mapping biopsy and intraoperative pathological diagnosis are performed, but it remains difficult 
to determine the extent of resection because of the obscure and irregular tumor margin. Thus, a 
new diagnostic method with more accuracy is required. Two-photon microscopy (TPM) enables 
us to observe the skin from the surface to the papillary dermis with a sub-cellular resolution in 3D 
non-invasively. In this study, we evaluated the possibility of TPM for a novel diagnostic tool for 
EMPD and analyzed the 3D distribution of Paget cells. TPM observation of freshly excised samples 
of EMPD revealed the existence of strong autofluorescence in corneal layer of EMPD but not in 
healthy skin or spinous layer of EMPD, suggesting that the autofluorescence is derived from dying 
Paget cells in corneal layer. Next, we utilized an approved fluorescent labeling probe of 5-ami-
nolevulinic acid (5-ALA). TPM observation of 5-ALA treated EMPD lesion revealed the existence 
of fluorescence-labeled cells in the basal and spinous layer, indicating that live Paget cells were 
detected by TPM. Finally, to obtain a 3D analysis of the EMPD lesion, we performed a whole-mount 
immunohistochemistry of EMPD by anti-cytokeratin 7 antibodies with optical clearing method for 
improving observational depth. These results suggest that TPM has a potential as a new non-invasive 
diagnostic tool for EMPD, and 3D visualization of EMPD may help to elucidate the pathogenesis 
and developmental property of EMPD.    
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Investigation of epithelial-mesenchymal transition by using in vitro human cell fusion system
T Buknicz,1 L Kemény,1 Z Kurgyis,1 Á Jakab,1 G Groma,2 L Kemény1 and I Németh1 1 
Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary and 2 
MTA-SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary
Epithelial-mesenchymal transition (EMT) is considered as a major step in the transformation of 
malignant cells gaining migratory capacity that is critical for progression and metastasis formation 
in cancer. Despite the growing number of reports on cancer and fibroblast fusion there is little 
known about EMT in human melanoma cell fusion. Previously we have shown that human mel-
anoma cells are able to fuse with stromal human dermal fibroblasts (HDFs) and that the resulting 
hybrid cells morphology is indistinguishable from parental HDFs. We hypothesize that melanoma 
and fibroblast fusion results in EMT therefore we aimed to apply a standardized in vitro cell fusion 
system to evaluate and visualize the process of EMT and phenotype switch of melanoma using 
human melanoma cell lines A375 and G361. Prior to coculturing myofibroblastic transformation of 
HDFs was induced by TGF-β. In order to obtain spontaneously fused cells melanoma cell lines were 
cocultured with induced myofibroblasts for 48hs. In order to visualize hybrid cells and to confirm 
cellular fusion fluorescence in situ hybridization was performed on cocultures identifying X and Y 
chromosomes of the male and female parental cells. In addition hybrid cells superimposed SMA 
immuncytochemistry highlighted phenotype switch of melanoma cells retaining myofibroblastic 
SMA marker detected by confocal microscopy. Based on our data from the applied in vitro cell 
fusion system human melanoma cells may have the capacity to fuse spontaneously with HDFs, 
acquiring mesenchymal morphology. Therefore human melanoma-fibroblast fusion might serve as 
a new alternative mechanism in EMT of melanoma.    
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Dermoscopy targeted skin microbiopsy is useful for RNA sampling in non-melanoma skin 
cancer lesions
L Lin, J Tan, H Soyer and T Prow Dermaology Research Centre, University of Queensland, 
Brisbane, QLD, Australia
A sub-millimeter skin micro-sampling device that is made up of three plates of 0.05 mm medical 
grade stainless steel, which has a chamber volumetric size of 0.003 mm3. This device enables 
collection of 5.9 ± 3.4 ng DNA and 9.0 ± 10.1 ng total RNA from skin tissue without the need of 
local anesthesia or sutures. Ideally, the device would be a minimally invasive means to sample skin 
lesions for molecular diagnosis. We asked whether the microbiopsy could be used to capture small 
amounts of mRNA from lesions suspected to be non-melanoma skin cancers. Clinical documenta-
tion consisted of patient history, clinical imaging, dermoscopy and clinical diagnosis. All lesions 
were subjected to >3 microbiopsies followed by conventional shave biopsy. The shaved tissue 
was subjected to histopathology diagnosis. Histopathological diagnoses included actinic keratosis, 
intraepithelial carcinomas, squamous cell carcinomas, basal cell carcinomas. Healthy skin from 
the volar forearm was also microbiopsied as a comparator. The microbiopsy samples were then 
subjected to total RNA extraction using a commercial kit. The quantity of total RNA was evaluated 
by Qubit and select samples were quantified by real-time PCR using an internally validated house 
keeping gene, RPLP0. The data show that the microbiopsy can be used to sample >1ng of total RNA 
from all skin lesions tested. These findings support the further development of the microbiopsy as a 
gateway device for discovering and validating molecular markers of skin disease.    
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The immunomodulatory and prognostic role of indoleamine-2,3-dioxygenase-1 in cutaneous 
T-cell lymphomas
PH Maliniemi,1 L Väkevä,1 T Lipsanen,1 K Dettmer-Wilde,2 P Oefner,2 ME Kadin3 and 
A Ranki1 1 Clinicum, Helsinki, Finland, 2 Institute of Functional Genomics, Regensburg, 
Germany and 3 Boston University and Roger Williams Medical Center, Boston, MA
ABSTRACT:Indoleamine-2,3-deoxygenase (IDO-1), catabolizing tryptophan (Trp) to kynurenine 
(Kyn), causes an immunosuppressive microenvironment in many neoplasias. In this study we iden-
tify the IDO-expressing cell subtypes in cutaneous T-cell lymphoma (CTCL) and determine the 
significance of serum Kyn/Trp catabolite levels. IDO-1 mRNA and protein expression was studied 
in 68 FFPE skin samples of mycosis fungoides (MF), lymphomatoid papulosis (LyP), lichen ruber 
planus (LRP) and subcutaneous panniculitic-like T cell lymphoma (SPTL), and in three CTCL cell 
lines. For co-expression, anti-CD33 (myeloid-derived suppressor cells, MDSC) and anti-CD163 
(tumor-associated macrophages, TAM) antibodies were used. Levels of 14 Trp metabolites were 
measured in 69 patient and healthy control sera by liquid chromatography–tandem mass spec-
trometry (LC-MS/MS). The relative expression of IDO-1 mRNA was markedly elevated in MF and 
LyP samples compared to LRP and also in the MF-derived cell line MyLa compared to the CD30+ 
CTCL lines Mac-1 and Mac-2A. Interestingly, IDO was co-expressed by CD33+ MDSCs in MF and 
in LyP and by the CD163+ TAMS in SPTL. The increase of IDO also associated with the eleveted 
level of Tregs in LyP as approximately 50% of the cases studied showed a moderate or strong FoxP3 
expression as well. Serum Kyn/Trp ratios showed significant increase in MF (p<0.05) compared with 
those of healthy controls and correlated with MF activity. We show that IDO is produced by the 
MF cell line MyLa and by CD33+ MDSCs in MF and in LyP but instead by CD163+ TAMs in SPTL. 
FoxP3+ Tregs, abundant in LyP, may contribute to the indolent clinical behavior. Serum Kyn/Trp 
ratio in MF associates to a progressive disease behaviour and may be a useful clinical indicator.   
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Expression of Sézary biomarkers in the blood of erythrodermic Mycosis Fungoides patients
C Hurabielle,2 L Michel,1 C Ram-Wolff,2 M Battistella,3 M Beylot-Barry,4 M d’Incan,5 
A Bensussan1 and M Bagot2 1 Inserm U976, Paris, France, 2 Dermatology, St Louis Hospital, 
Paris, France, 3 Pathology, St Louis Hospital, Paris, France, 4 Dermatology, Bordeaux 
University Hospital, Bordeaux, France and 5 Dermatology, Estaing University Hospital, 
Clermont-Ferrand, France
Several biomarkers (BM) such as KIR3DL2, Twist, T-plastin, and NKp46 have been specifically 
identified in the blood of patients having a Sézary Syndrome (SS). Their combination allows diagnosis 
of 100% of untreated SS patients. Herein, BM were assessed in all the B0 (circulating Sézary cells 
CSC≤5%) and B1 (CSC>5% but <1000/mm3) patients presenting Erythrodermic Mycosis Fungoides 
(EMF) diagnosed from 3 French Dermatological centers. 31 patients were included (20males, median 
age 64.2y). EMF was defined as erythroderma associated with suggestive histology of CTCL, but no 
SS criteria (B2=CSC>1000/mm3 or CD4/CD8≥10). BM gene expression was evaluated on isolated 
CD4+ T cells by qRT-PCR. 13 patients were B0 and 18 were B1. Among all EMF patients, 18/31 
(58%) expressed BM. B1 expressed significantly more BM than B0 patients (78% vs 31%, p=0.013), 
but significantly less than SS patients (78% vs 100%, p<0.001). BM expression detailed one by 
one was lower in B0 patients than in B1 patients, statistically significant for KIR3DL2 and T-plastin 
(p=0.011 and 0.045, respectively), and lower in B1 patients than in SS, statistically significant for 
TWIST and T-plastin (p<0.001). 31% of EMF patients do have Sézary BM in the absence of CSC, 
which contrast with results obtained in healthy donors (0% BM). 78% of the B1 patients expressed 
BM. Now, B1 patients are considered as pre-SS, having a poorer prognosis than B0. Thus, blood 
BM positivity might reflect appearance of the first events leading to a more aggressive disease since 
the biological functions of each Sézary BM has been shown to promote resistance to apoptosis of 
CD4+ tumour T-cells, and may have significant involvement in the progression of SS. Thus, BM 
expression may partially reflect clinical evolution of EMF from B0 to B2. This strongly argues for 
a spectrum of EMF up to SS.    
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Spectrum and risk of different types of cancer among heart transplant recipients
Z Secnikova,2 M Dzambova,2 D Gopfertova,3 Z Smerhovsky,3 L Hoskova1 and J Hercogova2 
1 Cardiology Dept., Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 
2 Dermatovenereology Dept., 2nd Medical Faculty Charles University Prague and Bulovka 
Hospital, Prague, Czech Republic and 3 Epidemiology Dept., 2nd Medical Faculty Charles 
University Prague and Bulovka Hospital, Prague, Czech Republic
Our aim was to perform the retrospective cohort study in Czech Republic on heart transplant recip-
ients (HTRs), compare the risks for different types of cancer and provide comprehensive analysis 
of skin cancer and other types of cancer morbidity from which we would be able to derive an 
evidence-based skin cancer surveillance program. A retrospective cohort study was performed to 
determine and compare standardized morbidity ratio (SMR) of different types of cancer developed 
after heart transplantation (HT). We analysed data obtained from medical documentation of 729 
HTRs transplanted between 1993 and 2011. We investigated 729 patients while 194 de novo 
malignancies had developed in 126 HTR (19.5 %). A total of 83 patients were excluded from further 
analysis due to a diagnosis of cancer before HT or within the first year after HT resulting in final 
count of 646 patients (525 men and 121 women). According to expectations, skin cancer was the 
most frequent type of malignancy (n=121) followed by lung cancer (n=22). Furthermore, median 
times to diagnosis, survival times, SMRs were evaluated for melanoma, prostate and other types of 
cancer. Cancer is a meaningful complication for long-term survival in HTR whereas post-transplant 
malignancies have variable clinical impact. Outcomes of this study are consistent with previous 
studies, with NMSC and lung cancer as the most frequent malignancies in HTR.    
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Down-regulation of ADAM-9 in human melanoma cells impairs their invasiveness 
N Moro, A Schönefuss, C Mauch and P Zigrino Department of Dermatology, University of 
Cologne, Cologne, Germany
Activities of metalloproteinases at the tumor stroma interphase are important for the development 
of several cancer types including melanoma. The metalloproteinase ADAM-9 is produced by mel-
anoma cells at the periphery of the invading tumor and by adjacent peritumoral stromal cells. 
In this study we aimed to investigate the role of ADAM-9 expression in human melanoma cells 
in tumor cell invasion. To address this aim, we used shRNA techniques to stably down-regulate 
ADAM-9 expression in highly invasive BLM melanoma cells (BLM-ADAM-9sh). Down-regulation 
of ADAM-9 in BLM cells was almost complete and led to altered cell morphology with reduced 
actin organization and a significant reduction in cell volume in suspension and monolayer con-
ditions. Furthermore, BLM-ADAM-9sh cells displayed increased cellular proliferation, as assessed 
by BrdU incorporation, and colony growth in soft agar. To address the relevance of these cellular 
changes in the process of invasion we used de-epidermized human skin composites as an in vitro 
invasion system. BLM-ADAM-9sh cells seeded on the dermal side of these composites invaded the 
underlying dermis similarly as observed by BLM-control-sh cells. In contrast, when plated on the 
basement membrane side of the composite, BLM-ADAM-9sh almost completely failed to invade this 
barrier. Reduced basement membrane penetration upon ADAM-9 down-regulation was not due to 
impaired cell migration as BLM-ADAM-9sh cells retained the ability to migrate over matrigel or a 
matrix deposited by HaCaT cells. However, we could detect a significant reduction of cell adhesion 
to matrigel and collagen IV, but not to laminin 332 and collagen I by BLM cells lacking ADAM-9 
expression when compared to control cells. These results suggest that alterations in cell adhe-
sion to matrix components is one important cause for decreased basement membrane penetration 
upon ADAM-9 is down-regulated. Taken together these data highlight the importance of ADAM-9 
expression for cell adhesive and likely proteolytic events necessary for melanoma cell invasion.   
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Notch regulated inflammatory pathway in Cutaneous Squamous Cell Carcinoma
P Arcidiacono, C Harwood and D Kelsell Centre for Cell Biology and Cutaneous Research, 
Blizard Institute, Queen Mary University of London, London, United Kingdom
Cutaneous squamous cell carcinoma (cSCC) that arise at sites of chronic inflammation can demon-
strate aggressive clinical behaviour. Sequencing analysis has revealed the somatic mutation spectra 
in cSCCs and clearly showed the key role of loss of function mutations in NOTCH1/2 in cSCCs. 
These genetic data support NOTCH1/2 as tumour suppressors. Here we have examined a panel of 
premalignant, primary and metastatic cSCC cell lines for NOTCH1/2 status to evaluate the impact 
in inflammatory pathways. Specifically we investigated how these cells respond to UVB irradiation 
with/without inhibitors of Notch activity. The majority of cSCC cell lines harboured missense 
mutations in Notch1/2. Immunoblotting showed variability in Notch1/2 expression and cleavage 
with subsequent changes to downstream targets (Hes-1 and Hey-1). As Notch can be regulated by 
A Disintegrin And Metalloprotease (ADAM)10 and possibly ADAM17, we investigated these two 
sheddases and associated substrates in four cSCC cell lines by immunoblotting which found an asso-
ciation between Notch level and ADAM17 processing. In addition, the levels of pro-inflammatory 
cytokines were measured by both qPCR and ELISA before and after UVB treatment. The results of 
this preliminary study suggest specific Notch-ADAM17 mediated pathways could be used for both 
diagnostic and targeted therapy in cSCC.    
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IL-32 induces IDO+CD1c+ dendritic cells and IDO+CD163+ macrophages: relevance to myco-
sis fungoides progression 
H Ohmatsu,1 D Humme,2 J Gonzalez,1 N Gulati,1 M Möbs,2 W Sterry2 and JG Krueger1 1 The 
Rockefeller University, New York, NY and 2 Department of Dermatology and Allergy, Skin 
Cancer Center Charité, Charité- Universitätsmedizin Berlin, Berlin, Germany
Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that 
fail to be controlled by protective immune mechanisms. Dendritic cells (DCs) and macrophages 
could encourage tumor cell growth in certain situations. The purpose of this study was to examine 
the role of IL-32, a cytokine highly expressed in MF lesions, on DCs, macrophages, other cytokines, 
and molecules in MF lesions. We used skin samples from healthy volunteers and MF patients to do 
immunohistochemistry, immunofluorescence, and RT-PCR. By using healthy volunteers’ bloods, 
we investigated the influence of IL-32 on monocytes’ differentiation. CD11c+ myeloid DCs and 
CD1c+ skin-resident DCs increased in MF lesions with disease progression. Depending on the 
other cytokines (IL-4, GM-CSF) present during in vitro culture of healthy volunteers’ monocytes, 
IL-32 increased the maturation of CD11c+ myeloid DCs and/or CD163+ macrophages, but IL-32 
alone showed a clear ability to promote DC differentiation from monocytes. DCs matured by 
IL-32 had the phenotype of skin-resident DCs, but more importantly also had high expression 
of the immunosuppressive molecule indoleamine 2,3-dioxygenase (IDO). The presence of DCs 
and macrophages with IDO was demonstrated in MF lesions at protein level. IDO mRNA levels 
increased with disease progression in MF lesions, and there was a strong correlation between 
IDO and IL-32 expression. In contrast, Foxp3 mRNA levels decreased with disease progression. 
Increasing expression of IL-10 across MF lesions was highly correlated with IL-32 and IDO, but 
not with Foxp3 expression. Thus, IL-32 could contribute to progressive immune dysregulation in 
MF by directly fostering development of immunosuppressive IDO-expressing myeloid DCs and 
macrophages, possibly in association with IL-10.    
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Intraperitoneal immunotherapy of melanoma ascites induces cancer cell senescence in 
humans
T Wieder,1 C Boss,1 E Brenner,1 H Braumüller,1 C Schulz,1 S Kayser,2 T Feuchtinger,2 
A Königsrainer3 and M Röcken1 1 Dermatology, University Medical Center, Tübingen, 
Germany, 2 Childrens Hospital, University Medical Center, Tübingen, Germany and 3 
Surgery, University Medical Center, Tübingen, Germany
Clinical studies using immune cell-regulating antibodies demonstrated the capacity of immuno-
therapy to control metastatic melanoma. Several death-inducing mechanisms, e.g. apoptosis and 
cellular lysis, have been demonstrated. Yet, the clinical data suggest that immunotherapy may also 
activate non-toxic pathways leading to cancer control. Cellular senescence is such a pathway, and 
an important endogenous barrier against cancer development. In line with this, we could show that 
the combined cytokine action of interferon-gamma (IFN-gamma) and tumor necrosis factor (TNF) 
induces senescence in human cancer cells, in vitro. However, it remains open whether immuno-
therapy of human cancers exclusively relies on killing or whether cytokine-induced senescence 
contributes to efficient immunotherapy of metastatic melanoma. In the present study, we first 
analyzed the pro-senescent effect of the therapeutically approved IFN-alpha in combination with 
TNF on human melanoma cell lines or on primary melanoma cells from ascites patients. We found 
that the combination of IFN-alpha and TNF, like IFN-gamma and TNF, induced a stable state of 
senescence in vitro, as demonstrated by cell cycle analysis, permanent growth arrest, induction of 
senescence-associated-beta-galactosidase (SA-beta-Gal), and upregulation of nuclear p16Ink4a. 
More importantly, intraperitoneal application of IFN-alpha into TNF-containing malignant ascites 
induced senescence in melanoma cells of two patients. Following IFN-alpha therapy, intraperitoneal 
melanoma cells started to express SA-beta-Gal, whereas the proliferation marker Ki67 was reduced. 
Simultaneously, melanoma cells became permanently growth-arrested, also in the absence of further 
cytokine therapy. Melanoma cells expressed p16Ink4a and were subsequently cleared from the 
peritoneum. Thus, besides killing, cytokine-induced senescence critically contributes to therapeutic 
cancer immune control in humans.    
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MicroRNA expression alterations during melanoma progression and metastasis development
A Komina, N Palkina, S Tsyrenzhapova, M Aksenenko, Y Shvetsova and T Ruksha 
Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
MicroRNA expression pattern characterized by tissue and disease specificity that makes these 
molecules attractive targets for developing new diagnostic and treatment approaches. In this study 
we investigated microRNA expression profiles in melanoma and melanocytic nevi by microarray. 
Our study revealed that of 5214 human microRNAs studied (in accordance to miRBase 20.0), 9 
microRNA were upregulated and 23 microRNAs were downregulated in melanoma as compared 
to melanocytic nevi. MiR-155 was the most upregulated in melanoma samples as compared to 
benign melanocytic lesions whereas miR-211 was the most downregulated microRNA type in 
melanoma. Hierarchical clusterization allowed to put melanoma and melanocytic nevi patients 
into two different groups. Predicted targets for differentially expressed microRNAs were obtained 
from TargetScan, MiRanda, DIANA-miR-Path online databases. Most of the genes were involved in 
cell cycle regulation, apoptosis, cell motility and invasion. Further estimation miR-155 expression 
in melanoma and melanocytic nevi by PCR real time did not reveal correlations on its levels with 
age, gender and melanoma characteristics such as localization, Breslow thickness, ulceration, pig-
mentation, lymphocytic infiltration, BRAF-status. In vivo studies of miR-155 expression in melanoma 
B16-bearing mice revealed its decreased levels in melanoma cells as compared to normal skin 
without alterations in melanoma primary tumor at pre-metastatic and metastatic stages. Evaluation 
of miR-155 levels in metastatic target organs revealed mir-155 elevation in lungs at metastatic phase 
that may correspond to its role in tumor progression and metastasis development. Previous research 
showed miR-155 elevated levels in several cancer types including breast, lung cancer, glioblastoma 
where miR-155 implicates in the apoptosis, cell proliferation and epithelial-mesenchymal transi-
tion regulation. MiR-155 functioning in melanoma remains unclear and needs further elucidation.   
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Outcomes following lymphoscintigraphy without sentinel node biopsy in patients who are 
elderly or have medical comorbidities
NA Ipenburg,1 O Nieweg,1 J Thompson1 and R Uren2 1 Melanoma Institute Australia, 
Wollstonecraft, NSW, Australia and 2 Sydney Medical School, Sydney, NSW, Australia
Sentinel-node biopsy (SNB) is the most powerful prognostic indicator in melanoma patients and 
has proven therapeutic benefit in a subset of them. However, it may be considered inappropriate in 
some patients. This study reports the clinical characteristics, management and outcomes for a series 
of patients managed by wide excision without SNB, but after preoperative lymphoscintigraphy to 
increase the reliability of clinical and ultrasound (US) follow-up. Our prospectively-collected data-
base was searched for patients with clinically localized cutaneous melanoma treated between 2000 
and 2009 in whom lymphoscintigraphy was performed but SNB was intentionally not scheduled. 
Of the 3523 patients who had lymphoscintigraphy, 161 (4.6%) did not undergo SNB because of 
age and/or comorbidities. On average, these patients were older than the 2945 patients who had 
SNB (78 vs 57 years, p<0.001), more often had head-neck melanomas (34% vs 16%, p<0.001), 
and had more advanced melanomas (Breslow thickness 2.5 mm vs 1.8 mm; p<0.001) with a 
higher mitotic rate (median 5/mm2 vs. 3/mm2; p=0.002). Of these 161 patients, 148 (92%) were 
followed with high-resolution US of their SNs at each follow-up visit, which identified 31% of the 
nodal recurrences before they were clinically apparant. Patients who did not have SNB had worse 
overall survival (HR=1.40, 95% CI 1.01-1.95) and regional node disease-free survival (HR=1.95, 
95% CI 1.19-3.19) than patients who did undergo SNB, but melanoma-specific survival (HR=1.26, 
95% CI 0.74-2.13) and recurrence-free survival were not significantly different (HR=1.11, 95% 
CI 0.77-1.59). Compared to SN-positive patients, node-positive patients without SNB had more 
involved nodes when a delayed lymphadenectomy was performed (mean 3.7 vs. 1.7, p=0.03), but 
melanoma-specific survival was not significantly different (HR=0.66, 95% CI 0.23-1.86). Lympho-
scintigraphy with US follow up of previously identified SNs is a reasonable management option to 
avoid SNB in patients who are elderly or have comorbidities.    
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French national cohort of melanoma patients from the RIC-Mel network
A Khammari,2 L Thomas,1 J Lacour,3 C Lebbe,4 B Guillot,5 A Dupuy,6 L Larue,7 E Varey,2 
M Leccia8 and B Dreno2 1 Dermatology department, CHU Lyon sud, Lyon, France, 2 
Oncodermatology department, CHU de Nantes, Nantes, France, 3 Dermatology department, 
CHU de Nice, Nice, France, 4 Dermatology department, Hôpital Saint Louis, APHP, 
Paris, France, 5 Dermatology department, CHU de Montpellier, Montpellier, France, 6 
Dermatologye department, CHU de Rennes, Rennes, France, 7 CNRS UMR3347/Inserm 
U1021, Orsay, France and 8 Dermatology department, CHU de Grenoble, Grenoble, France
The national cohort was set up by the RIC-Mel network (Clinical Investigation Network on mela-
noma) to collect data from melanoma patients in order to promote translational and epidemiolog-
ical projects as well as to optimize the achievements of clinical trials. To achieve these goals, a 
database was launched in 2012 in collaboration with the National Centre for Healthcare Products 
Trial Management. The database was approved by the French health authorities. Collected data 
describes patient characteristics, disease history and progress until death and if biological samples 
are available. Thanks to the 46 participating sites, the database gives a permanently updates map-
ping of melanoma treated in France with the key information needed for any research projects. In 
3 years, more than 12 500 patients were included: 70% of primary stages and 30% of locoregional/
metastatic stages. Four pharmaceutical companies have signed a partnership with our network. 
In 2013, a first company used data prior to the registration of a targeted therapy and to realize 
medico-economic modelling. Recently, another company used data to estimate the proportion of 
patients meeting the selection criteria for a clinical trial. A new company wishes to create an eCRF 
for a post-ATU (Authorisation for Temporary Use) project, available on the database. Moreover, 
the High Health Authority requested the RIC-Mel network to study the target population of a new 
therapeutic product. Monocentric data were also analysed for feasibility and rational studies. All 
of these projects demonstrate the interest of the database created by the RIC-Mel network and that 
is an efficient instrument to satisfy clinical or translational researches.    
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MITF p.E318K in melanoma patients with fast growing melanoma independent of the presence 
of CDKN2A causative mutations
J Puig-Butille,2 M Potrony,1 P Aguilera,1 C Badenas,2 C Carrera,1 G Tell,1 L del Pozo,3 
J Conejo-Mir,4 J Malvehy1 and S Puig1 1 Dermatology Department, Melanoma Unit, Hospital 
Clínic de Barcelona. IDIBAPS.Centro de Investigación Biomédica en Red en Enfermedades 
Raras (CIBERER), Barcelona, Spain, 2 Molecular Biology and Genetics Department, 
Melanoma Unit, Hospital Clínic de Barcelona. IDIBAPS. Centro de Investigación Biomédica 
en Red en Enfermedades Raras (CIBERER), Barcelona, Spain, 3 Department of Dermatology, 
Hospital Universitari Son Espases, Palma de Mallorca, Spain and 4 Servicio de Dermatologia, 
Hospital Universitario Virgen del Rocio, Sevilla, Spain
CDKN2A, encoding p16INK4A and p14ARF, is the main high-penetrance melanoma susceptibil-
ity gene. MITF p.E318K also predisposes to melanoma. The aim of the study was to evaluate the 
prevalence of the MITF p.E318K in Spanish melanoma patients and assess the association with 
clinical and phenotypic features. MITF p.E318K was assessed in 531 patients: 271 p16INK4A 
wild-type multiple primary melanoma patients (MPM), 191 p16INK4A wild-type index cases from 
melanoma-prone families and a single melanoma diagnosis and 69 index cases from families with 
p16INK4A mutations. The genetic results were correlated with clinical and phenotypic features. The 
prevalence of MITF p.E318K was 1.9% (9/462) in all p16INK4A wild-type melanoma patients, 2.6% 
(7/271) in MPM and 2.9% (2/69) in index cases of families with p16INK4A mutations. MITF p.E318K 
was associated with an increased melanoma risk (OR=3.1, p<0.01), especially in MPM (OR=4.2, 
p<0.01) and high nevi count (OR=8.4, p<0.01). Two fast growing melanomas were detected in two 
MITF p.E318K carriers during follow-up. In conclusion, MITF p.E318K, besides melanoma risk, is 
associated with a high nevi count and could play a role in fast growing melanomas. MITF p.E318K 
genetic testing, should not exclude patients with known mutations in CDKN2A. Strict dermatological 
surveillance and periodical self examination should be encouraged in this context.    
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Correlation of Merkel cell polyomavirus positivity with PDGFRa mutations and survivin 
expression in Merkel cell carcinoma
M Batinica,1 B Akgül,2 S Schilling,2 C Mauch1 and P Zigrino1 1 Dermatology, University 
of Cologne, Cologne, Germany and 2 Virology, University of Cologne, Cologne, Germany
Merkel cell carcinoma is a neuroendocrine cancer of the skin postulated to originate through Merkel 
cell polyomavirus (MCPyV). MCPyV is detected broadly within the population,but only a part of the 
infected people develop MCC. It is thus conceivable that together, virus and for example mutations, 
are necessary for disease development. However, apart from a correlation between MCPyV positivity 
or mutations and MCC development, unknown is the association with progressive disease. We ana-
lyzed MCPyV positivity, load and integration in MCC as well as presence of mutations in PDGFRa 
and TP53 genes and correlated these with clinical features and disease progression. Therefore we 
studied a MCC population group of 64 patients. MCPyV positivity, load and integration in parallel 
to mutations in the PDGFRa and TP53 were analyzed on genomic DNA from MCC specimens. 
In addition, expression of PDGFRa, survivin and p53 proteins was analyzed in tissues specimens. 
All these parameters were analyzed as function of patient’s disease progression status. Among our 
patient 83% of MCCs were positive for the MCPyV and among these 36% also displayed virus-T 
integration. Viral load was highest in patients with progressive disease. We detected more than 
one mutation within the PDGFRa gene and identified two new SNPs in 36% of MCC patients. No 
mutations were found in TP53 gene. Survivin was expressed in 78% of specimens. We could not 
correlate either mutations in PDGFR or expression of PDGFR, p53 and Survivin either to the disease 
progression or to the MCPyV positivity. In conclusion, our data indicate that the viral positivity 
when associated with high viral load, correlates with poor disease outcome. Frequent mutations 
in the PDGFRa gene and high Survivin expression were found in MCC independent of the viral 
positivity. These data suggest that these three factors independently contribute to Merkel cell car-
cinoma development and that only the viral load can be used as indicator of disease progression 
in virus positive patients.    
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A novel biomarker, CADM-1/TSLC1 for aggressive Sézary syndrome: comparison with the 
soluble form in sera
M Yamaguchi,1 T Hamada,1 S Morizane,1 M Sugaya,2 H Iwata,3 K Fujii,4 M Imada,5 
K Morishita,6 K Ohshima7 and K Iwatsuki1 1 Dermatology, Okayama Univ., Okayama, Japan, 
2 Dermatology, Tokyo Univ., Tokyo, Japan, 3 Dermatology, Hokkaido Univ., Sapporo, Japan, 
4 Dermatology, Kagoshima Univ., Kagoshima, Japan, 5 Laboratory Medicine, Okayama 
Univ. Hosp., Okayama, Japan, 6 Medical Science, Miyazaki Univ., Miyazaki, Japan and 7 
Pathology, Kurume Univ., Kurume, Japan
Recently, we found that the CADM1/TSLC1 was often expressed by Sézary cells as well as adult 
T-cell leukemia/lymphoma (ATLL) cells, while no significant increase of CADM1/TSLC1+ cells was 
detected in inflammatory skin conditions. To understand the clinical significance of CADM1/TSLC1 
expression in Sézary syndrome (SS), we have further examined cellular and soluble CADM1/TSLC1 
in leukemic cells of 6 patients with Sézary syndrome (SS), in comparison with those of cell lines 
derived from mycosis fungoides (MF)/SS (n=3), ATLL (n=2), ALCL (n=4) and B-cell lymphoma (n=6), 
and peripheral blood (PB) samples from reactive T-cell LPDs (n=9) and normal subjects (n=19). Of 
6 patients with SS, 4 patients with aggressive illness revealed increased percentages of the CADM1/
TSLC1+ cells in the CD3+CD4+ fraction, ranging from 29.4 to 74.5%. Both CADM1/TSLC1 and 
CCR4 were highly expressed by the skin infiltrates of SS, but the CADM1/TSLC1+ cells did not 
always co-expressed CCR4 in the PB. The remaining 2 patients with SS, who were in remission or 
indolent clinical course, showed no increase. The CADM1/TSLC1+ cells were observed in 2 of 3 
MF/SS-derived cell lines: 99.3 and 99.7%, respectively, and to a lesser extent in the ATLL and ALCL 
cell lines. No induction of CADM1/TSLC1 was observed in CD3/CD28-stimulated normal T-cells 
although they began to express HLA-DR and CD25. Soluble CADM1/TSLC1 was detected not more 
than 20 μg/mL in serum samples from SS (n=7), MF (n=21) and ALCL (n=6), and culture supernatants 
of T-cell lymphoma cell lines including SS-derived cell lines (Hut78 and SeAx). Two of 6 serum 
samples from ATLL, however, contained more than 60 μg/mL of soluble CADM1/TSLC1. The expres-
sion of cellular CADM1/TSLC1, but not the soluble form, is a diagnostic marker for aggressive SS.   
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Retrospective analysis of clinicopathological characteristics of pregnancy associated 
melanoma
M Fabian,1 V Tóth,1 B Somlai,1 J Hársing,1 E Kuroli,1 F Rencz,2 D Kuzmanovszki,1 J Szakonyi,1 
B Tóth1 and S Kárpáti1 1 Dermatology, Venereology and Dermatooncology, Semmelweis 
University, Budapest, Hungary and 2 Department of Health Economics, Corvinus University, 
Budapest, Hungary
Pregnancy associated melanoma (PAM) by definition appears during pregnancy or within one year 
after delivery. In this retrospective study we analyzed the pathological characteristics and survival 
rate of PAM and matched the data with non-pregnant age- and stage-matched control female 
and male patients. Between 2003-2014, 34 pregnant women (aged 22-40 years) were diagnosed 
with melanoma at the Department of Dermatology, Venereology and Dermatooncology of the 
Semmelweis University. During the pathological procession histologic subtype, Breslow thickness 
and Clark level, mitotic rate, peritumoral inflammation, tumor cell type, presence of satellite and 
vascular invasion, as well as, ulceration, necrosis and regression of melanoma were analyzed and 
related to clinical data. Primary tumor location and clinical staging, disease course, local recur-
rence and metastases, 5-year survival rate, other tumor development before or after the diagnosis 
of melanoma have also been documented. There was no significant difference between PAM and 
melanoma of non-pregnant women or men in the histologic subtype, Breslow thickness, Clark level, 
mitotic rate, tumor cell type, regression, vascular invasion, ulceration, necrosis, tumor location, 
neither in the survival during the observation period. Peritumoral inflammation was higher in PAM 
group and beside that, the presence of mild inflammation was significantly higher in PAM group 
compared to non-pregnancy associated melanoma (NPAM) women group. The high incidence of 
PAM (34/336, 10.12%) observed among women with melanoma in reproductive age (18-45 years) 
could be related to the suspected hormone dependency of the tumor, while the generally favorable 
prognosis of PAM by the early diagnosis.    
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Inhibition of human vitamin D3 metabolism by imatinib and nilotinib 
LM Kroschwald,1 JT Tauer,2 M Suttorp,2 N Zimmermann,1 C Guenther1 and A Bauer1 1 
Department of Dermatology, University Hospital “Carl Gustav Carus”, TU Dresden, Dresden, 
Germany and 2 Department of Pediatrics, Division of Pediatric Hematology and Oncology, 
University Hospital “Carl Gustav Carus”, TU Dresden, Dresden, Germany
Chronic myeloid leukemia (CML) is characterized by an upregulated activity of the tyrosine kinase 
(TK) BCR-ABL1. TK inhibitors like imatinib (IMA) or nilotinib (NIL) inhibit the TK BCR-ABL1 but exert 
also “off target” effects on bone metabolism in adult and pediatric patients with CML. As vitamin D3 
(VD3) is involved in the complex cycle of bone remodelling, we investigated the influence of IMA 
and NIL on the VD3 metabolism i) in HaCaT cells and ii) in cultured outer root sheath keratinocytes 
(KC) from hair follicles of TKI treated children with CML. Cells were incubated with 25 μM 7-dehy-
drocholesterole and 1 μM IMA or 1 μM NIL, which resemble therapeutic plasma concentrations 
and exposed to UVB for 24 hours, 48 hours, or 72 hours, respectively. Concomitantly, specific 
inhibitors were applied to analyze the inhibition of VD3  processing cytochrome P450 isoenzyme 
family by TKI. KC of TKI treated children were cultured for 28 days. Calcidiol and Calcitriol levels 
were determined by using ELISA technique. In HaCaT cells and compared to TKI-untreated controls 
IMA and NIL reduced calcitriol levels to 50% and 10%, respectively. Control studies with VID400 
or ketoconazole in the absence of TKI did not influence calcidiol levels (range: 90 – 110 ng/1*106 
cells) while calcitriol levels were decreased by about 60 %. IMA in the presence of VID400 increased 
calcidiol levels by 600 % but did not influence calcitriol synthesis. Co-incubation of IMA and 
ketoconazole increased calcitriol levels by 200 %. The same effect was detected by repeating the 
described experiments using keratinocytes of TKI treated children and healty subjects. Furthermore, 
compared to KC of healthy subjects, KC of TKI treated children revealed no differences in levels 
of calcidiol and calcitriol. In conclusion, IM and NIL interfere with the VD3 cascade due to their 
metabolization by CYP27B1 and might explain the disturbance in bone metabolism.    
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SCC metastases in organ transplant recipients: a kidney transplant cohort and a review of 
the literature
E Plasmeijer, R Genders, M Westhuis-van Elsäcker and J Bouwes Bavinck Dermatology, 
LUMC, Leiden, Netherlands
Cutaneous squamous cell carcinoma (SCC) in organ transplant recipients (OTR) show more aggres-
sive behaviour with a greater tendency toward deep invasion, local recurrences and possibly metas-
tasis in comparison with the immunocompetent population. We investigated the incidence of 
metastasized SCC in kidney transplant recipients and its related risk factors in a cohort of patients, 
transplanted in our tertiary referral clinic between March 1966 and October 2007. Moreover, the 
available literature was reviewed for an SCC metastasis rate in OTR. Articles were selected with 
at least 50 patients with an SCC and a mean follow up of at least 24 months. Of 2136 patients in 
the cohort, 215 developed an SCC. Of those, 15 developed a metastasis. The lifetime incidence of 
SCC-metastasis is 5.7%. The risk for a first SCC to metastasize is 2.7%. The overall risk for a random 
de novo carcinoma to metastasize is <1.0%. Tumors in the head/neck region more often show 
metastatic behaviour (OR 1.7; 95% CI 0.5-5.9). In total 5282 articles were reviewed and 24 were 
selected. One case-control study showed a 4.6% metastasis rate (7/153) in OTR versus 1.3% (2/154) 
in the immunocompetent population. In 22 articles SCC of all locations were grouped together. 
19 studies were retrospective cohort studies, 2 RCT and one prospective study. In total there were 
4753 patients in all studies. The majority of patients had received a kidney. Metastasis rates were 
found between 0.7 and 16%, giving a mean metastasis rate of 7.2%. One article focused on SCC 
on the hand only, finding a metastasis rate of 4% (3/86), while an article focused on cutaneous 
head and neck SCC found a metastatic rate of 19% (19/101). This study showed no increased 
metastasis risk of SCC in kidney transplant recipients in comparison with earlier published data in 
the immunosuppressed population. However comparison studies are needed for more information.   
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Inversed correlation of miRNA expression and differentiation stage of cutaneous squamous 
cell carcinoma in the immunocompetent population
B Burger,1 B Stoecklin,1 S Herms,1 A Arnold,2 A Volz2 and PH Itin2 1 University Hospital 
Basel and University of Basel, Basel, Switzerland and 2 University Hospital Basel, Basel, 
Switzerland
Cutaneous squamous cell carcinoma (cSCC) development in the immunocompetent population 
is promoted by an accumulation of DNA damages through UV-light exposure. Usually, cSCC 
develops from precancerous lesions (actinic keratoses (AK)), which can shift into either well-, mod-
erately-, or poorly-differentiated tumors. Tumor-stage-specific differences in the expression pattern 
of mRNA are known, however, data addressing the expression pattern of microRNAs (miRNA), 
which regulate mRNA stability in cSCC of the general population, are scarce. We hypothesized 
that the development of different stages of cSCC goes along with characteristic changes in miRNA 
expression. Therefore, we screened AK as well as several emerging tumor stages for changes in 
miRNA expression in comparison to expression in healthy epidermis. Suitable tumor areas were 
carefully localized in FFPE tissue samples and isolated by core biopsy, preventing contamination by 
non-tumorous tissue. MiRNA profiling using array technology pointed out an increased number of 
deregulated miRNAs in the lower differentiated cSCC tissues compared to well differentiated cSCC 
tissue and AK. Single miRNAs showed a grade of deregulation linear to the differentiation stage 
of analyzed tissue. Using target prediction programs we identified changes in miRNAs which are 
conform to reported mRNA changes. Finally, deregulated miRNAs in cSCC identified by our scan 
point to target mRNAs, whose altered expression might be key for cancer progression.    
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Malignant melanoma in Niamey: a report from the Niger Cancer Registry 
S Mamoudou Garba,1 H Hami,2 H Mahamadou Zaki,1 A Soulaymani,2 H Nouhou1 and 
A Quyou2 1 Laboratory of Pathological Anatomy and Cytology, Faculty of Health Sciences, 
Abdou Moumouni University, Niamey, Niger and 2 Laboratory of Genetics and Biometry, 
Faculty of Science, Ibn Tofaïl University, Kenitra, Morocco
Malignant melanoma is an aggressive malignancy. The aim of this study is to describe the epide-
miological and histological features of malignant melanoma in Niamey, capital of the Niger. This 
is a descriptive retrospective analysis of melanoma cases, reported between 1993 and 2009 to the 
National Cancer Registry of Niger, established in 1992, in the Laboratory of Pathological Anatomy 
and Cytology at the Abdou Moumouni University in Niamey. During this 17-year period, 33 cases 
were diagnosed with melanoma in Niamey, accounting for 0.67% of all cancer cases reported during 
the study period. Of these, 60.6% were females, with a female-male ratio of 1.54. The average 
age at diagnosis was 53±14.6 years for all patients (range 26-78 years), 60.7±15.4 years for men 
and 48±12 years for women. More than two-thirds (66.7%) of people diagnosed with the disease 
were aged 50 years or older at the time of diagnosis, with 63.6% of new cancer cases occurring 
among those aged 50-74 years. The most prevalent ethnic group were the Djerma-Sonrai (51.5%) 
and Haoussa (36.4%). The most common sites for melanoma were the skin [C44] (87.9%) and eye 
[C69.9] (12.1%). In 90.9% of cases, the initial diagnosis of melanoma was established by patho-
logical examination. The most common histological type of melanoma was malignant melanoma 
[M-8720/3] (69.7%). The evaluation of melanoma epidemiological characteristics is difficult in 
Niger, the patients refuse to consult, and are reluctant to perform histopathological examination. 
They prefer consult traditional healers.    
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Podoplanin expression in peritumorial keratinocytes predicts aggressive behavior in extra-
mammary Paget’s disease
Z Cho,1 J Asai,1 T Arita,1 H Takenaka,1 E Konishi,2 A Yanagisawa2 and N Katoh1 1 
Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan and 2 Surgical 
Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Recent studies have demonstrated podoplanin expression in several tumors, which has been asso-
ciated with lymph node metastasis and poor prognosis. Podoplanin expression in cancer-associated 
fibroblasts (CAFs) also correlates with tumor progression in several cancers. However, podoplanin 
expression and its association with extramammary Paget’s disease (EMPD) remain unclear. To 
clarify the aggressiveness of podoplanin in EMPD, podoplanin expression in tumor cells, CAFs and 
peritumorial keratinoctes was examined by immunohistochemistry in tissue samples from 33 EMPD 
patients. Podoplanin was not identified in tumor cell. Podoplanin expression in CAFs was identified 
in 10 patients (30.3%), however, it was not correlated with characteristics of tumor progression such 
as tumor thickness and dermal invasion. Podoplanin expression in peritumorial keratinocytes was 
observed in 22 patients (66.7%), including the 13 patients (59.0%) with dermal invasion. In contrast, 
only 2 of 11 patients with negative podoplanin expression in peritumorial keratinocytes (18.1%) 
exhibited dermal invasion. Podoplanin expression in peritumorial keratinocytes was also associated 
tumor thickness (P〈0.005). These results suggested that the presence of podoplanin expression in 
peritumorial keratinocytes correlates with aggressive behavior in EMPD, and may therefore serve 
as ausefull prognostic marker for patients with EMPD.    
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High dose intravenous ascorbic acid therapy on locally advanced basal cell cancer – report 
of 2 cases
A Bánvölgyi, K Lörincz, K Nemeth, A Keszeg, N Gyongyosi, N Wikonkál and S Kárpáti 
Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, 
Hungary
The anti-cancer effect of intravenously administered high-dose ascorbic acid is a hot-topic in oncol-
ogy. We examined its effect in two patients suffering from locally advanced basal cell cancer where 
no other treatment option was available, before the era of the Smo-inhibitors. Based on previous 
reports in the literature we administered intravenous ascorbic acid. We found that in our two cases 
the cancer showed partial response. The therapy was well tolerated without major side effects. The 
mode of action is not fully understood yet, however we show results of anti-angiogenesis effect 
and discuss the possible mechanism of actions based on the literature. According to our limited 
experience with high dose intravenous ascorbic acid therapy is an effective and safe therapy for 
locally advanced basal cell cancers. We consider its use as monotherapy or possibly as adjuvant 
therapy for Smo-inhibitors in future.    
      
